Boosting Kidney Organoid Differentiation: How DMSO Treatment Enhances Efficiency and Maturation

Anna Long Dec 02, 2025 66

This article explores a significant methodological advancement in kidney organoid generation: the use of low-dose Dimethyl Sulfoxide (DMSO) to precondition human induced pluripotent stem cells (hiPSCs).

Boosting Kidney Organoid Differentiation: How DMSO Treatment Enhances Efficiency and Maturation

Abstract

This article explores a significant methodological advancement in kidney organoid generation: the use of low-dose Dimethyl Sulfoxide (DMSO) to precondition human induced pluripotent stem cells (hiPSCs). Aimed at researchers and drug development professionals, we detail how a simple 24-hour treatment with 1-2% DMSO reshapes the cellular and epigenetic landscape of hiPSCs, leading to a more efficient differentiation into nephron progenitor cells and robust, tubular kidney organoids. Covering foundational science, step-by-step protocols, optimization strategies, and comparative validation, this resource provides a comprehensive guide to implementing this technique to create superior in vitro models for biomedical research and nephrotoxicity screening.

The Science of Priming Pluripotency: Understanding How DMSO Prepares Stem Cells for Kidney Fate

The Challenge of Efficiency in Kidney Organoid Differentiation

Frequently Asked Questions (FAQs)

FAQ 1: What is the primary benefit of using DMSO to improve kidney organoid differentiation? Treating human induced pluripotent stem cells (hiPSCs) with a low dose of Dimethyl Sulfoxide (DMSO) before differentiation primes the cells, making them more receptive to differentiation signals. This pre-treatment enhances the efficiency of generating key kidney progenitor cells and subsequent kidney organoids, particularly improving the expression of the critical nephron progenitor marker SIX2 [1] [2].

FAQ 2: What is the recommended DMSO treatment protocol? The established method involves treating hiPSCs with 1-2% (v/v) DMSO for 24 hours, immediately before initiating the standard kidney organoid differentiation protocol [1] [2]. This treatment affects the gene expression of pluripotent transcription factors and the epigenetic landscape, priming the cells for differentiation.

FAQ 3: How does DMSO treatment affect the pluripotent state of hiPSCs? DMSO treatment influences the "primed state" of hiPSCs. It alters the expression of pluripotency markers, changes the epigenetic landscape, and modifies colony morphology. Furthermore, it halts cells in the G1 phase of the cell cycle by preventing the phosphorylation of retinoblastoma, which is thought to regulate the early transitional states of hiPSCs toward differentiation [2].

FAQ 4: What are the major challenges in kidney organoid differentiation beyond efficiency? Even with improved protocols, challenges remain. These include the presence of off-target, non-renal cell populations (e.g., neuronal, muscle), the overall immaturity of the organoids which resemble first-trimester fetal kidneys, and the lack of a patent, integrated vasculature. Controlling self-organization and reducing batch-to-batch variation are also significant hurdles [3].

FAQ 5: Can kidney organoids be cryopreserved for future use? Yes, but it requires careful optimization. A 2024 study shows that vitrification (a rapid freezing technique using a combination of 20% DMSO and 20% Ethylene Glycol with sucrose) is superior to conventional slow-freezing for kidney organoids. Vitrification preserved over 90% viability and maintained critical structures like podocytes and tubules, whereas slow-freezing methods often damaged podocyte clusters [4].

Troubleshooting Guides

Common Problems & Solutions
Problem Category Specific Issue Potential Causes Recommended Solutions
Differentiation Efficiency Low expression of nephron progenitor markers (e.g., SIX2) Suboptimal hiPSC starting population; Inefficient mesoderm induction. Pre-treat hiPSCs with 1-2% DMSO for 24 hours before differentiation [1] [2].
High percentage of off-target cell types Limited control over mesodermal patterning; Uncontrolled self-organization. Fine-tune growth factor concentrations; Consider using synthetic hydrogels to provide more precise biochemical and biophysical cues [3].
Organoid Structure & Function Lack of mature, functional glomeruli Immaturity of organoids; Protocol does not support full maturation. Explore prolonged culture with tailored microenvironmental cues; Investigate co-culture with stromal cells to provide necessary signals [3].
Tubular dilation or cyst formation Genetic defects; Suboptimal differentiation conditions. This can be a disease phenotype. For KCNJ16-related tubulopathy, drug screening in organoid models has identified statins (e.g., Simvastatin + C75) as a potential treatment to prevent lipid accumulation and collagen deposition [5].
Cryopreservation Low viability or loss of specific cell types after thawing Ice crystal formation damaging delicate structures; Inadequate penetration of cryoprotectants. Use vitrification over slow-freezing. The V1 vitrification method (20% DMSO, 20% Ethylene Glycol) best preserves podocytes and tubules [4].

The table below summarizes key quantitative findings from research on DMSO priming for kidney organoid differentiation.

Metric Finding / Measurement Experimental Context
Optimal DMSO Concentration 1% - 2% (v/v) [1] [2] Added to mTeSRPlus medium for hiPSC culture.
Optimal Treatment Duration 24 hours [1] [2] Treatment applied prior to differentiation initiation.
Key Outcome Enhanced expression of SIX2 [1] [2] Metanephric mesenchyme nephron progenitor marker, measured at day 9 of differentiation.
Cellular Mechanism Halts cells in G1 phase of cell cycle [2] DMSO prevents phosphorylation of retinoblastoma protein via PI3K pathway alteration.
Cryopreservation Viability Vitrification (V1): ~91% viability [4] Post-thaw viability of kidney organoids.
Slow-Freezing (SF1/SF2): ~79-83% viability [4] Post-thaw viability of kidney organoids.

Detailed Experimental Protocols

Protocol 1: DMSO Priming of hiPSCs for Enhanced Kidney Organoid Differentiation

This protocol is adapted from Kearney et al. (2025) [1] [2] and is designed to be integrated with established kidney differentiation protocols, such as the Morizane et al. (2017) method.

Key Principle: Pre-treatment of hiPSCs with low-dose DMSO to prime the cells for more efficient differentiation towards nephron progenitors.

Materials:

  • hiPSC lines (e.g., LUMC, HUMIMC101, HUMIMC107 used in the study)
  • mTeSRPlus medium (STEMCELL Technologies)
  • Geltrex (1% solution, ThermoFisher)
  • Dimethyl Sulfoxide (DMSO)
  • Gentle Cell Dissociation Reagent (STEMCELL Technologies) or Accutase
  • Y-27632 (ROCK inhibitor)

Methodology:

  • hiPSC Culture and Seeding: Maintain hiPSCs as colonies on Geltrex-coated plates in mTeSRPlus medium. When ready for differentiation, create a single-cell suspension using Accutase and seed them at a defined density onto Geltrex-coated plates in mTeSRPlus medium supplemented with 10 µM Y-27632.
    • Example cell densities from the study:
      • LUMC line: 1.0 x 10⁴ cells/cm²
      • HUMIMC101 line: 9.0 x 10³ cells/cm²
      • HUMIMC107 line: 7.0 x 10³ cells/cm² [2]

  • Pre-differentiation Culture: The day after seeding, replace the medium with fresh mTeSRPlus medium (without Y-27632) and culture for another 24 hours.

  • DMSO Treatment (Priming): On the third day, replace the medium with mTeSRPlus medium supplemented with the desired concentration of DMSO (e.g., 1% or 2% v/v). Incubate the cells for 24 hours.

    • Control: A control group should be maintained in parallel with mTeSRPlus medium containing no DMSO.

  • Initiation of Differentiation: After the 24-hour DMSO treatment, remove the DMSO-containing medium. Proceed directly with your chosen stepwise kidney organoid differentiation protocol, starting with the induction of primitive streak and intermediate mesoderm [2].

Workflow Diagram: DMSO Priming & Differentiation

G Start Culture hiPSCs as Colonies A Seed as Single Cells with ROCK Inhibitor Start->A B 24h Pre-culture in mTeSRPlus A->B C 24h Treatment with 1-2% DMSO B->C D Initiate Kidney Organoid Differentiation Protocol C->D End Differentiated Kidney Organoid (Enhanced SIX2+ Progenitors) D->End

Protocol 2: Functional Assessment - Bioenergetic Profiling of Kidney Organoids

Metabolic dysfunction is a key feature of many kidney diseases. This protocol outlines how to assess the bioenergetics of kidney organoids using Seahorse technology [6].

Key Principle: Measure the Oxygen Consumption Rate (OCR) and Extracellular Acidification Rate (ECAR) in single kidney organoids to determine their mitochondrial and glycolytic function.

Materials:

  • Differentiated kidney organoids
  • Seahorse XF96 Analyzer (Agilent)
  • Seahorse XF Cell Mito Stress Test Kit (Agilent)
  • DMEM-based Seahorse assay medium (pH 7.4)
  • Metabolic inhibitors: Oligomycin, FCCP, Rotenone/Antimycin A

Methodology:

  • Organoid Preparation: Transfer individual kidney organoids to a Seahorse XF96 cell culture microplate, one organoid per well.
  • Equilibration: Incubate the plate for 45-60 minutes in a CO₂-free incubator at 37°C to allow temperature and pH equilibration.
  • Mitochondrial Stress Test:
    • The Seahorse analyzer sequentially injects the following compounds while measuring OCR and ECAR in real-time:
      • Oligomycin: ATP synthase inhibitor; reveals ATP-linked respiration.
      • FCCP: Uncoupler; reveals maximal respiratory capacity.
      • Rotenone & Antimycin A: Complex I and III inhibitors; reveal non-mitochondrial respiration.
  • Data Analysis: Normalize bioenergetic parameters (Basal Respiration, ATP Production, Maximal Respiration, Spare Capacity) to the organoid's DNA or protein content to account for size variability [6].

Pathway Diagram: Mitochondrial Stress Test Interpretation

G Mito Mitochondrial Function Base Basal Respiration (Total mitochondrial respiration under baseline conditions) Mito->Base ATP ATP-linked Respiration (OCR drop after Oligomycin = respiration used for ATP production) Base->ATP Max Maximal Respiration (OCR peak after FCCP = total respiratory capacity) ATP->Max Spare Spare Respiratory Capacity (Max - Basal respiration) Indicator of metabolic flexibility Max->Spare

The Scientist's Toolkit: Essential Research Reagents

The table below lists key reagents used in the featured DMSO priming and kidney organoid research.

Reagent / Material Function in the Protocol Specific Example / Note
hiPSCs The starting cell population with the potential to differentiate into any cell type, including kidney lineages. Lines used in foundational studies include LUMCi004-C, TISSUi001-A, and TISSUi007-A, derived from urine and blood [2].
DMSO (Dimethyl Sulfoxide) A priming agent that alters the pluripotent state, epigenetics, and cell cycle of hiPSCs to enhance subsequent differentiation efficiency into nephron progenitors [1] [2]. Use high-purity, cell culture-grade. Final concentration of 1-2% v/v.
Geltrex A solubilized basement membrane extract used as a substrate to coat culture surfaces, supporting the attachment and growth of hiPSCs and organoids. A common choice for 3D culture and differentiation protocols.
mTeSRPlus A defined, serum-free medium optimized for the maintenance and growth of human pluripotent stem cells. Serves as the base medium for hiPSC culture and the vehicle for DMSO priming [2].
CHIR99021 A small molecule inhibitor of GSK-3. Used in differentiation protocols to activate Wnt signaling and direct cells toward primitive streak and mesoderm fates. A critical reagent in many kidney organoid protocols, including Morizane and Takasato methods [6] [3].
Y-27632 (ROCK inhibitor) A small molecule that inhibits Rho-associated kinase. It increases the survival of single cells and cell clusters by preventing anoikis (cell death after detachment). Used during cell passaging and seeding to improve viability [2] [7].
FGF-9 & BMP-7 Key growth factors used in subsequent steps of kidney organoid differentiation to promote the survival and expansion of nephron progenitor cells. Part of the "nephron progenitor expansion and maintenance" phase in established protocols [6].

hiPSCs and the 'Primed' State of Pluripotency

Understanding Pluripotency States: Naïve vs. Primed

What are the key functional differences between naïve and primed hiPSCs?

Human induced pluripotent stem cells (hiPSCs) can exist in vitro in a spectrum of interconvertible pluripotent states, primarily categorized as "naïve" and "primed." Understanding their differences is crucial for experimental design. The table below summarizes the core distinctions.

Table 1: Characteristics of Naïve vs. Primed hiPSCs

Feature Naïve State Primed State
Developmental Analogue Pre-implantation epiblast [8] [9] Post-implantation epiblast [8] [2]
Colony Morphology Dome-shaped, 3D spheroids [10] [11] Flat, 2D colonies [2]
Differentiation Potential Higher and broader [10] [11] Lower and more restricted [10]
Gene Editing Efficiency Higher (due to increased homologous recombination) [10] Lower [10]
Signaling Dependencies LIF/STAT3 [12] FGF2 and Activin A [2]
Common Culture Methods Specific small molecule inhibitors [9]; specialized synthetic matrices (e.g., poly-Z [10], Chitosan [11]) Conventional feeder cells or ECM matrices (e.g., Vitronectin, Matrigel) [10] [2]

Under conventional culturing conditions, most hiPSCs are maintained in the primed state, which is poised for rapid lineage specification but has a more restricted differentiation potential compared to the naïve state [8] [10] [2]. Furthermore, conventional culture platforms based on extracellular matrices (ECMs) like vitronectin tend to maintain hiPSCs in this primed state [10].

G Pluripotency Spectrum and Transitions Naive Naïve State (Pre-implantation) Formative Formative State (Early Post-implantation) Naive->Formative In vitro differentiation Primed Primed State (Late Post-implantation) Formative->Primed  In vitro maturation Primed->Naive Reprogramming (TNT, Naïve media)

Troubleshooting Guide: FAQs on the Primed State

Why does the primed state of my hiPSCs matter for kidney organoid differentiation efficiency?

The primed state represents a later developmental stage. Differentiation protocols must guide these cells backward through earlier developmental steps before specifying target lineages, which can be inefficient. Evidence suggests that modulating the primed state can enhance differentiation outcomes. For instance, treating primed hiPSCs with a low dose (1-2%) of Dimethyl Sulfoxide (DMSO) for 24 hours prior to differentiation has been shown to enhance the expression of key nephron progenitor markers, such as SIX2, and improve the efficiency of kidney organoid formation [1] [2] [13]. DMSO is thought to alter the epigenetic landscape and gene expression of pluripotency transcription factors, "priming" the cells for a more efficient differentiation response [2].

My hiPSC colonies appear flat and spread out. Is this normal for the primed state?

Yes. A flat, two-dimensional colony morphology is a characteristic of hiPSCs cultured in the primed state [2]. In contrast, naïve hiPSCs typically form compact, dome-shaped colonies or 3D spheroids [10] [11]. If your differentiation protocol requires a naïve-like state, this morphology indicates a need for conversion.

How can I convert my primed hiPSCs to a naïve-like state without complex media formulations?

Recent advances in biomaterials offer simplified approaches. Culture on specific synthetic polymer matrices or biopolymers can induce and maintain naïve-like features. For example:

  • Cross-linked cyclosiloxane polymer matrix (poly-Z): Supports hiPSC growth as spheroids and upregulates naïve-state gene expression, even after long-term culture [10].
  • Chitosan membranes: Promote the self-assembly of hiPSCs into 3D spheroids and sustain a naïve-like pluripotent state with higher stemness, facilitating direct differentiation into cells from the three germ layers [11].

These platforms provide a more straightforward and cost-effective alternative to complex cocktail-based naïve media [10] [11].

Objective: To pre-condition primed hiPSCs with low-dose DMSO to increase the efficiency of subsequent nephron progenitor and kidney organoid differentiation.

Background: This protocol is based on research demonstrating that a 24-hour DMSO treatment alters the expression of pluripotency factors and the epigenetic landscape of hiPSCs, leading to improved differentiation toward metanephric mesenchyme and more efficient tubular kidney organoid formation [2] [13].

Materials and Reagents

Table 2: Key Research Reagent Solutions

Item Function in Protocol Example/Source
hiPSCs Starting cell material in primed state e.g., LUMCi004-C, HUMIMC101 lines [2]
mTeSRPlus Medium Maintenance medium for primed hiPSCs STEMCELL Technologies [2]
Dimethyl Sulfoxide (DMSO) Pre-conditioning agent to enhance differentiation [1] [2] [13]
Geltrex Extracellular matrix for 2D cell culture ThermoFisher [2]
Accutase Enzyme for generating single-cell suspension STEMCELL Technologies [2]
Y-27632 (ROCKi) Inhibits apoptosis to improve cell survival after passaging Tocris [2]
Detailed Methodology

  • Seeding hiPSCs for Differentiation:

    • Dissociate a well of primed hiPSCs using 1 mL Accutase. Incubate at 37°C for 10 minutes.
    • Generate a single-cell suspension and resuspend in mTeSRPlus medium supplemented with 10 µM Y-27632.
    • Seed the cells onto a culture plate coated with 1% Geltrex at a density optimized for your hiPSC line (e.g., 1.0 × 10^4 cells/cm² for the LUMC line) [2].

  • Pre-conditioning with DMSO:

    • 24 hours after seeding, replace the medium with fresh mTeSRPlus.
    • On the following day (day 3 of culture), replace the medium with mTeSRPlus supplemented with DMSO.
    • Experimental Groups:
      • Negative Control: mTeSRPlus with no DMSO.
      • Treatment Group 1: mTeSRPlus with 1% (v/v) DMSO.
      • Treatment Group 2: mTeSRPlus with 2% (v/v) DMSO.
    • Incubate the cells for 24 hours [2] [13].

  • Commencing Kidney Organoid Differentiation:

    • After the 24-hour DMSO treatment, remove the DMSO-containing medium.
    • Proceed immediately with your standard kidney organoid differentiation protocol, such as the stepwise 2D monolayer-based method developed by Morizane et al. (2017) [2].
Expected Results and QC Checkpoints
  • Flow Cytometry: After DMSO treatment, you may observe changes in the surface expression of pluripotency markers (TRA-1-60, TRA-1-81, SSEA-3, SSEA-4) and intracellular markers (OCT3/4, SOX2) compared to the untreated control [2].
  • Differentiation Outcome: On day 9 of kidney organoid differentiation, expect to see enhanced expression of the key nephron progenitor marker SIX2 in the DMSO-treated groups compared to the control, indicating improved specification of metanephric mesenchyme [2] [13].

G DMSO Pre-conditioning Workflow A Seed primed hiPSCs on Geltrex B 24h: Change to fresh mTeSRPlus A->B C 24h: Treat with mTeSRPlus + 1-2% DMSO B->C D Begin kidney organoid differentiation protocol C->D

Table 3: Summary of Experimental Data from Key Studies

Experimental Approach Key Measured Outcome Result Citation
Deconvolution of 213 hiPSC lines Variation in pluripotency state proportions Remarkable variation in the relative fraction of formative and primed state cells across different lines. [8]
DMSO pre-treatment Expression of nephron progenitor marker SIX2 at day 9 of differentiation Enhanced expression of SIX2 was observed, indicating improved nephron progenitor specification. [2] [13]
Culture on poly-Z polymer matrix Pluripotency state gene expression Up-regulation of naïve-state genes compared to cells on vitronectin (primed state control). [10]
Transient Naive Treatment (TNT) reprogramming Epigenetic similarity to hES cells Produced hiPS cells with fewer epigenetic aberrations and higher differentiation efficiency. [9]
Culture on Chitosan membranes Long-term culture duration Maintained hiPSC pluripotency and normal karyotype for up to 365 days (approx. 100 passages). [11]

Troubleshooting Guides and FAQs

Frequently Asked Questions

Q1: What is the typical concentration range for DMSO when used as a differentiation enhancer for hiPSCs? For pretreatment of human induced pluripotent stem cells (hiPSCs) to enhance differentiation, a concentration of 1–2% (v/v) DMSO in culture medium is most commonly used and has been shown to be effective across numerous cell lines. This concentration range has demonstrated efficacy in enhancing differentiation into kidney organoids and other lineages without causing significant cytotoxicity [2] [14].

Q2: How long should hiPSCs be pretreated with DMSO prior to differentiation? The standard pretreatment duration is 24 to 48 hours. A 24-hour treatment is generally sufficient for most human embryonic stem cell (hESC) and hiPSC lines. Cell lines with slower growth rates may benefit from a 48-hour incubation with DMSO, with a medium change to fresh DMSO-containing medium after the first 24 hours [14].

Q3: Why does DMSO pretreatment improve differentiation efficiency in hiPSCs? DMSO enhances differentiation capacity through multiple interconnected mechanisms:

  • Cell Cycle Regulation: It increases the proportion of cells in the early G1 phase by preventing phosphorylation of retinoblastoma protein, which primes cells for cell fate changes [2] [14].
  • Epigenetic Modulation: It alters the epigenetic landscape, including histone modifications, which affects gene expression patterns [2].
  • Gene Expression Changes: It influences the expression of pluripotency transcription factors and genes involved in cytoskeletal dynamics, cilium assembly, and cell adhesion [2].

Q4: What specific improvements in kidney organoid differentiation have been observed with DMSO pretreatment? Studies have shown that DMSO pretreatment of hiPSCs specifically enhances the expression of SIX2, a key marker for metanephric mesenchyme nephron progenitor cells, after 9 days of kidney organoid differentiation. This leads to more robust development of tubular kidney organoids with improved differentiation protocol efficiency [2] [15].

Q5: At what concentration does DMSO become cytotoxic in cell culture systems? Cytotoxicity is cell-type and exposure-time dependent. Generally, concentrations below 1% show minimal cytotoxicity across most cell lines. One systematic study found DMSO at 0.3125% showed minimal cytotoxicity across all tested cancer cell lines except MCF-7 at multiple time points. However, cytotoxic effects become more variable at higher concentrations and depend on cell type and exposure duration [16].

Q6: Can DMSO affect other cellular processes relevant to differentiation studies? Yes, beyond differentiation, studies have shown that low-dose DMSO can influence various cellular processes including:

  • Cell Migration: DMSO at very low concentrations (0.0005%-0.1%) can induce cell migration in human normal hepatic cells by disturbing the balance between matrix metalloproteinases and their inhibitors [17].
  • Viral Infection: DMSO can increase infectability of HepaRG cells by human adenovirus in a dose-dependent manner, affecting viral entry rather than replication [18].

Troubleshooting Common Experimental Issues

Problem: Inconsistent differentiation results after DMSO pretreatment. Potential Causes and Solutions:

  • Cause 1: Variable cell density at time of DMSO treatment.
  • Solution: Standardize seeding density according to specific cell line requirements. For kidney organoid differentiation, optimal densities vary by hiPSC line (e.g., 1×10⁴ cells/cm² for LUMC lines, 9×10³ cells/cm² for H101 lines) [2].
  • Cause 2: DMSO concentration or treatment duration not optimized for specific cell line.
  • Solution: Perform a dose-response experiment with 1% and 2% DMSO for both 24h and 48h durations to determine optimal conditions for your specific cell line [14].

Problem: Unexpected cytotoxicity observed after DMSO treatment. Potential Causes and Solutions:

  • Cause 1: DMSO concentration too high for specific cell type.
  • Solution: Test lower concentrations (0.5-1%) and reduce treatment duration. Validate with cell viability assays [16].
  • Cause 2: Improper handling of DMSO stocks leading to oxidation or contamination.
  • Solution: Use fresh, high-quality DMSO from reputable suppliers. Aliquot stock solutions to avoid repeated freeze-thaw cycles. Ensure proper storage conditions [19] [20].

Problem: Poor kidney organoid formation despite DMSO pretreatment. Potential Causes and Solutions:

  • Cause 1: Inadequate characterization of starting hiPSC population.
  • Solution: Validate pluripotency using conventional markers (OCT3/4, SOX2, TRA-1-81, TRA-1-60, SSEA3, SSEA4) via flow cytometry before DMSO treatment [2].
  • Cause 2: Suboptimal timing for initiating differentiation protocol post-DMSO treatment.
  • Solution: Begin differentiation immediately after the 24-48 hour DMSO pretreatment period without passaging cells [14].

Experimental Protocols

Detailed Methodology: DMSO Pretreatment for Enhanced Kidney Organoid Differentiation

Background This protocol is adapted from established methods for DMSO pretreatment of hiPSCs to enhance differentiation efficiency into kidney organoids, particularly following the Morizane et al. (2017) stepwise 2D monolayer-based protocol [2] [14].

Materials Required

  • hiPSCs (multiple lines validated, including LUMC0031iCTRL08, HUMIMC101, HUMIMC107)
  • mTeSRplus medium (STEMCELL Technologies)
  • Dimethyl sulfoxide (DMSO), cell culture grade
  • Geltrex (1%) coated cell culture plates
  • Gentle cell dissociation reagent or Accutase
  • Phosphate buffered saline (PBS)
  • Y-27632 dihydrochloride (ROCK inhibitor)
  • Differentiation media components as per Morizane et al. protocol

Step-by-Step Procedure

  • hiPSC Culture and Maintenance

    • Maintain hiPSCs as colonies on 1% Geltrex-coated plates with mTeSRplus medium.
    • Passage cells once colonies reach appropriate size using gentle cell dissociation reagent.
    • Break up colonies by gentle pipetting and reseed at desired splitting ratio (typically 1:10) [2].

  • Seeding hiPSCs for Differentiation

    • Dissociate hiPSCs with Accutase at 37°C for 10 minutes.
    • Prepare single cell suspension and resuspend in mTeSRplus medium supplemented with 10 µM Y-27632 dihydrochloride.
    • Seed onto Geltrex-coated plates at cell line-specific densities:
      • 1×10⁴ cells/cm² for LUMC lines
      • 9×10³ cells/cm² for HUMIMC101
      • 7×10³ cells/cm² for HUMIMC107 [2]
    • Incubate for 24 hours at 37°C, 5% CO₂.

  • DMSO Pretreatment

    • After 24 hours, prepare DMSO treatment medium: mTeSRplus supplemented with 1-2% (v/v) DMSO.
    • Aspirate existing medium and replace with DMSO-containing medium.
    • Incubate for 24 hours at 37°C, 5% CO₂ [2] [14].
    • For 48-hour treatment, replace with fresh DMSO-containing medium after first 24 hours.

  • Initiation of Kidney Organoid Differentiation

    • Following DMSO pretreatment, immediately begin kidney organoid differentiation using the established stepwise 2D monolayer-based protocol [2].
    • Continue with differentiation protocol as standard, monitoring for enhanced SIX2 expression around day 9.

Critical Steps and Timing

  • The optimal window for initiating differentiation is immediately after DMSO pretreatment.
  • Cell density at time of DMSO treatment is critical - aim for 80-90% confluency.
  • Use consistent DMSO stock solutions to avoid batch-to-batch variability.

Table 1: DMSO Effects on hiPSC Differentiation and Cellular Processes

Parameter Effect of DMSO Concentration Experimental System Reference
Kidney Organoid Differentiation Enhanced SIX2+ nephron progenitor generation 1-2% for 24h hiPSCs following Morizane protocol [2]
Cell Cycle Distribution Increased G1 phase proportion 1-2% for 24h Multiple hESC/hiPSC lines [14]
Cytotoxicity Threshold >30% viability reduction >1% for 24h Various cancer cell lines [16]
Cell Migration Induced migration via MMP/TIMP imbalance 0.0005%-0.1% Human normal hepatic L02 cells [17]
Viral Infectability Increased adenovirus infection 1% for 2 weeks Differentiated HepaRG cells [18]

Table 2: DMSO Safety Thresholds Across Cell Types

Cell Type Safe Concentration Toxic Concentration Exposure Time Assessment Method
Various Cancer Lines ≤0.3125% (most lines) >0.3125% (MCF-7) 24-72h MTT assay [16]
hiPSCs 1-2% >2% 24-48h Morphology, pluripotency markers [2] [14]
Human Hepatic L02 <0.0005% ≥0.0005% 24h Cell migration, viability [17]
HepaRG <1% >1% 2 weeks Cell viability, infection assays [18]

Signaling Pathways and Mechanisms

Diagram 1: Mechanisms of DMSO in Enhancing hiPSC Differentiation

G cluster_cell_cycle Cell Cycle Regulation cluster_epigenetic Epigenetic Modulation cluster_gene_exp Gene Expression Changes DMSO DMSO Treatment (1-2%, 24-48h) G1_phase G1 Phase Arrest DMSO->G1_phase Rb_protein RB Protein Activation DMSO->Rb_protein chromatin Chromatin Landscape Changes DMSO->chromatin pluripotency Pluripotency Factor Modulation DMSO->pluripotency differentiation Enhanced Differentiation Capacity G1_phase->differentiation cell_cycle Cell Cycle Checkpoint Activation Rb_protein->cell_cycle Rb_protein->differentiation cell_cycle->differentiation histone_mod Histone Modifications chromatin->histone_mod chromatin->differentiation histone_mod->differentiation cytoskeletal Cytoskeletal & Adhesion Gene Alterations pluripotency->cytoskeletal pluripotency->differentiation cytoskeletal->differentiation

Mechanisms of DMSO in Enhancing hiPSC Differentiation: This diagram illustrates the primary mechanisms through which DMSO pretreatment enhances differentiation capacity in hiPSCs, including cell cycle regulation, epigenetic modulation, and gene expression changes that collectively prime cells for improved differentiation outcomes [2] [17] [14].

Diagram 2: Experimental Workflow for DMSO-Enhanced Kidney Organoid Differentiation

G cluster_key_outcomes Key Outcomes hiPSC_culture hiPSC Culture & Maintenance (mTeSRplus on Geltrex) seeding Seeding for Differentiation (Cell line-specific density) hiPSC_culture->seeding dmso_treatment DMSO Pretreatment (1-2% for 24-48 hours) seeding->dmso_treatment differentiation Kidney Organoid Differentiation (Morizane et al. protocol) dmso_treatment->differentiation analysis Analysis & Validation (SIX2 expression, morphology) differentiation->analysis outcome1 Enhanced SIX2+ Nephron Progenitor Generation analysis->outcome1 outcome2 Improved Tubular Kidney Organoid Formation analysis->outcome2 outcome3 Increased Differentiation Protocol Efficiency analysis->outcome3

Experimental Workflow for Kidney Organoid Differentiation: This workflow outlines the key steps in utilizing DMSO pretreatment to enhance the efficiency of kidney organoid differentiation from hiPSCs, culminating in improved generation of nephron progenitors and tubular structures [2] [14].

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for DMSO-Enhanced Differentiation Experiments

Reagent/Category Specific Examples Function/Application Key Considerations
Cell Culture Medium mTeSRplus, DMEM, William's E Maintenance and differentiation of hiPSCs Medium choice affects DMSO impact; William's E shows stronger effects in hepatic models [18]
Extracellular Matrix Geltrex, Matrigel Substrate for cell attachment and growth Coating consistency critical for reproducible differentiation outcomes [2] [14]
DMSO Solvent Cell culture grade DMSO Differentiation enhancement, cryopreservation Quality and freshness vital; avoid oxidized stocks [19] [20]
Cell Dissociation Reagents Accutase, Gentle Cell Dissociation Reagent Passaging and harvesting cells Gentle dissociation preserves cell viability for differentiation [2]
ROCK Inhibitor Y-27632 dihydrochloride Enhances survival of single cells Essential for seeding single cells after passaging [2] [14]
Characterization Antibodies TRA-1-81, TRA-1-60, SSEA3, SSEA4, OCT3/4, SOX2 Pluripotency validation pre-differentiation Quality controls for starting cell population [2]
Differentiation Markers SIX2, PODXL, LRP2, GATA3 Kidney organoid differentiation assessment SIX2 key for nephron progenitor evaluation [2]
Viability Assays MTT, Cell Counting Kit-8 Cytotoxicity assessment Critical for determining DMSO safety margins [16] [17]

Dimethyl sulfoxide (DMSO) is a widely used solvent in biological research with profound, concentration-dependent effects on stem cell pluripotency, differentiation, and colony morphology. Within the specific context of improving kidney organoid differentiation, recent research indicates that precise DMSO treatment can significantly enhance protocol efficiency by modulating the pluripotent state of stem cells prior to differentiation induction. Treatment of human induced pluripotent stem cells (hiPSCs) with low-dose DMSO (1-2%) affects gene expression of pluripotent transcription factors, alters the epigenetic landscape, and modifies hiPSC colony morphology, ultimately promoting more efficient differentiation into nephron progenitors and complex kidney organoids [1] [21]. This technical resource provides detailed guidance for researchers leveraging DMSO to improve renal differentiation protocols.

Technical Reference: DMSO Effects Data

Quantitative Effects of DMSO on Pluripotency and Differentiation

Table 1: DMSO concentration effects on different cell systems

Cell Type DMSO Concentration Exposure Duration Effects on Pluripotency Effects on Differentiation Citation
Mouse ESCs (without LIF) 0.1%, 0.5%, 1.0%, 2.0% 4 days Upregulated pluripotency markers Reduced expression of ectodermal (β-tubulin3), mesodermal (Hand1), and endodermal (Foxa2, Sox17) markers [22]
Human iPSCs (for kidney organoids) 1-2% Not specified Altered expression of pluripotency genes, changed colony morphology Enhanced SIX2 expression (nephron progenitor marker), improved kidney organoid differentiation [1] [21]
Human ESCs (for endoderm/hepatic) 0.25% to 2% 4 days (definitive endoderm stage) Efficient down-regulation of OCT4 & NANOG Increased definitive endoderm markers (SOX17, CXCR4, GATA4); enhanced hepatic differentiation [23]
Primary Neurons ≥0.50% 12-48 hours N/A (differentiated cells) Marked neurite retraction, reduced viability and NeuN expression [24]
Primary Astrocytes 0.50% and 1.00% 24-48 hours N/A (differentiated cells) Enhanced proliferation and GFAP expression (reactive gliosis) [24]

Experimental Workflow for DMSO Conditioning

The following workflow diagram illustrates the key methodological steps for using DMSO to enhance kidney organoid differentiation, based on established protocols [1] [21]:

G Start Culture hiPSCs to appropriate confluence A Apply DMSO (1-2%) in culture medium Start->A B Incubate for specified duration A->B C Assess colony morphology changes B->C D Analyze pluripotency gene expression (qPCR) B->D E Proceed to kidney organoid differentiation protocol C->E D->E F Evaluate SIX2 expression at day 9 of differentiation E->F G Assess tubular kidney organoid formation F->G

Troubleshooting Guides

Common DMSO Issues and Solutions

Table 2: Troubleshooting DMSO-related experimental problems

Problem Potential Cause Solution Prevention Tips
Excessive cell death after DMSO treatment DMSO concentration too high; rapid direct addition to cells Use lower concentrations (≤0.25% for sensitive cells); pre-dilute DMSO in medium before adding to culture Always use pharmaceutical or electronic grade DMSO; test concentration ranges [24]
Inconsistent differentiation results between batches Variable DMSO purity; improper storage leading to oxidation Source high-purity DMSO from reputable suppliers; store in airtight, dark containers; use fresh aliquots Establish standardized quality control checks for all reagent batches
Poor kidney progenitor differentiation despite DMSO Incorrect timing of DMSO application; wrong concentration for specific cell line Optimize DMSO treatment window (before/during early differentiation); test 0.5-2% range for hiPSCs Include positive controls in each experiment to confirm DMSO activity [1]
Altered colony morphology not as expected DMSO affecting cell-extracellular matrix interactions Ensure consistent extracellular matrix coating; monitor morphology changes daily Use computer-assisted morphology analysis for quantitative assessment [25]
Residual DMSO toxicity in final organoids Inadequate washing steps after DMSO treatment Implement thorough washing protocol after DMSO exposure; consider longer recovery phases Validate DMSO removal through analytical methods if necessary

DMSO Concentration Guidelines for Different Cell Types

Table 3: Safe DMSO concentration ranges by cell type

Cell Type Safe Concentration (No Adverse Effects) Toxic Concentration Key Morphological Changes
Primary Neurons ≤0.25% (up to 24h) ≥0.50% Neurite retraction at ≥0.50%; dramatic viability loss at ≥1.00% [24]
Primary Astrocytes ≤1.00% (12h exposure) ≥5.00% Process maintenance at 0.50-1.00%; reactive gliosis induction [24]
Human iPSCs 1-2% (for priming) >2% (context-dependent) Altered colony morphology; compactness changes [1]
Mouse ESCs 0.1-2.0% (without LIF) >2% Maintained undifferentiated colony morphology without LIF [22]
Chinese Hamster Ovary (CHO) Cells Varies by application Dose-dependent Striking morphology changes on agar; reduced glycosaminoglycans [25]

Frequently Asked Questions

Q1: How does DMSO enhance kidney organoid differentiation efficiency? A1: DMSO pretreatment alters the epigenetic landscape and gene expression of pluripotency transcription factors in hiPSCs, priming them for more efficient differentiation. This results in enhanced expression of SIX2, a key marker for nephron progenitors, and improved formation of tubular kidney organoids [1] [21].

Q2: What is the recommended DMSO concentration for human iPSC conditioning? A2: For kidney organoid applications, research indicates that 1-2% DMSO is effective for conditioning hiPSCs. However, concentration optimization is recommended for specific cell lines and differentiation protocols, as effectiveness may vary [1].

Q3: Can DMSO replace LIF in stem cell culture? A3: In mouse ESCs, DMSO (0.1-2.0%) has been shown to sustain pluripotency in the absence of leukemia inhibitory factor (LIF), suggesting it may partially substitute for LIF function in maintaining undifferentiated states [22].

Q4: How quickly does DMSO affect pluripotency gene expression? A4: The timeframe varies by cell type. In human ESCs undergoing definitive endoderm differentiation, DMSO efficiently downregulated pluripotency genes (OCT4, NANOG) within the 4-day differentiation protocol [23].

Q5: Why does DMSO cause different effects in different cell types? A5: DMSO's varied effects stem from its multiple mechanisms of action, including membrane permeability alterations, epigenetic modifications, and differential gene regulation. Cell-type specific responses occur due to variations in transcriptional networks, membrane composition, and metabolic states [22] [23] [24].

Q6: What safety precautions are necessary when using DMSO in research? A6: Always use high-purity, sterile DMSO of appropriate grade (pharmaceutical grade for cell culture). Use protective equipment as DMSO rapidly penetrates skin and can carry other compounds with it. Ensure proper storage in airtight containers away from moisture [26] [27].

Research Reagent Solutions

Essential Materials for DMSO Experiments

Table 4: Key reagents for DMSO-related pluripotency research

Reagent/Material Function Application Notes
Pharmaceutical Grade DMSO High-purity solvent for cell culture Essential for reproducible results; prevents contaminants from causing variable effects [26]
Activin A Differentiation factor for definitive endoderm Used with DMSO to enhance endoderm formation in hESCs [23]
Matrigel Extracellular matrix for cell culture Provides consistent substrate for colony growth and morphology studies [23]
Anti-SIX2 Antibody Nephron progenitor marker detection Critical for assessing kidney differentiation efficiency after DMSO treatment [1]
qPCR Reagents for Pluripotency Markers Gene expression analysis Quantifies changes in OCT4, NANOG, SOX2 after DMSO exposure [22] [23]
Cryopreservation Medium Cell storage DMSO's cryoprotectant properties are valuable for stem cell banking [27]

Mechanism of DMSO Action in Pluripotency Regulation

The following diagram illustrates the current understanding of how DMSO influences pluripotency and differentiation pathways, particularly in the context of kidney organoid differentiation:

G cluster_1 Direct Cellular Effects cluster_2 Pluripotency State Modulation cluster_3 Enhanced Kidney Differentiation DMSO DMSO Treatment (1-2%) A1 Altered Gene Expression DMSO->A1 A2 Epigenetic Modifications DMSO->A2 A3 Colony Morphology Changes DMSO->A3 A4 Membrane Permeability DMSO->A4 B1 Primed for Differentiation A1->B1 A2->B1 A3->B1 A4->B1 B2 Tet Family Gene Activation B1->B2 C1 Increased SIX2 Expression B1->C1 B2->C1 Inhibits differentiation methylation C2 Improved Nephron Progenitor Formation C1->C2 C3 Tubular Kidney Organoid Development C2->C3

Reshaping the Epigenetic Landscape for Directed Differentiation

Technical Support Center

Troubleshooting Guide: Frequently Asked Questions

Q1: Our hiPSCs show poor differentiation efficiency into nephron progenitor cells (NPCs). What is a potential pre-treatment to improve this? A: Pre-treating hiPSCs with a low concentration (1-2%) of Dimethyl Sulfoxide (DMSO) for 24 hours before initiating differentiation can enhance efficiency. DMSO alters the epigenetic landscape and gene expression of pluripotent transcription factors, priming the cells for more efficient differentiation into SIX2-positive NPCs [1] [2].

Q2: What is the recommended protocol for DMSO pre-treatment? A: Culture hiPSCs to an appropriate confluence. Replace the standard mTeSRplus medium with mTeSRplus supplemented with 1% or 2% (v/v) DMSO. Incubate the cells for 24 hours, after which the DMSO-containing medium should be removed, and the standard kidney organoid differentiation protocol should be initiated [2].

Q3: How do we verify that DMSO pre-treatment is effectively priming our hiPSCs? A: You can assess the treatment's impact through several methods:

  • Flow Cytometry: Analyze changes in the expression of pluripotency surface markers (TRA-1-60, TRA-1-81, SSEA3, SSEA4) and intracellular transcription factors (OCT4, SOX2) after the 24-hour DMSO treatment [2].
  • Colony Morphology: Monitor changes in hiPSC colony morphology in real-time; DMSO treatment often induces observable morphological changes [1] [2].
  • Gene Expression Analysis: After initiating differentiation, quantify the expression of key markers like SIX2 on day 9. A significant increase indicates improved NPC specification [1].

Q4: From a mechanistic perspective, how does DMSO influence the epigenetic "primed state" of hiPSCs? A: While the full mechanism is under investigation, current research indicates that DMSO treatment influences the epigenetic landscape, potentially by altering histone modifications. The balance of specific histone marks, such as the repressive H3K27me3 and the activating H3K4me3, is crucial for maintaining pluripotency and enabling differentiation. DMSO may help shift this balance, making the cells more receptive to differentiation signals [1] [28].

Key Experimental Protocols

Protocol 1: Assessing Pluripotency Marker Expression via Flow Cytometry This protocol is used to evaluate the effect of DMSO pre-treatment on the "primed state" of hiPSCs [2].

  • Cell Preparation: After 24 hours of DMSO treatment, wash the hiPSCs with PBS and dissociate them into a single-cell suspension using Accutase.
  • Staining for Surface Markers: Resuspend ~1x10^6 cells in a flow cytometry stain buffer containing fluorophore-conjugated antibodies against TRA-1-60, TRA-1-81, SSEA3, and SSEA4. Incubate for 30 minutes in the dark at 4°C.
  • Staining for Intracellular Markers: For intracellular markers like OCT4 and SOX2, fix the cells with 4% PFA for 30 minutes after dissociation. Then, permeabilize the cells with a buffer containing 0.1% Triton X-100 before incubating with the respective antibodies.
  • Analysis: Analyze the stained cells using a flow cytometer (e.g., BD Accuri C6). Use compensation controls and analysis software (e.g., FloJo) to determine the expression levels of each marker.

Protocol 2: Kidney Organoid Differentiation and NPC Quantification This is based on the established protocol by Morizane et al. (2017), as used in the cited DMSO studies [2].

  • hiPSC Seeding: Seed a single-cell suspension of hiPSCs on Geltrex-coated plates at a density optimized for your cell line (e.g., 1x10^4 cells/cm²).
  • DMSO Pre-treatment: On the third day of culture, treat cells with mTeSRplus medium containing 0% (control), 1%, or 2% DMSO for 24 hours.
  • Directed Differentiation: Initiate a stepwise, 2D monolayer-based differentiation protocol toward metanephric mesenchyme.
  • Marker Quantification: On day 9 of differentiation, analyze the expression of the key nephron progenitor marker SIX2, as well as other kidney lineage markers (e.g., PODXL, LRP2, GATA3), typically via immunostaining or flow cytometry, to assess differentiation efficiency.

Table 1: Key Findings from DMSO Pre-treatment Studies

Parameter Investigated Experimental Finding Significance for Differentiation
DMSO Concentration 1-2% (v/v) in culture medium [2] Establishes an effective and non-cytotoxic range for pre-treatment.
Treatment Duration 24 hours prior to differentiation induction [2] Provides a defined window for epigenetic priming.
Impact on Pluripotency Alters gene expression of core pluripotency transcription factors (OCT4, SOX2) and affects colony morphology [1] [2] Indicates a shift from a stable "primed" state, making cells more amenable to lineage specification.
Key Outcome Measure Enhanced expression of SIX2 protein after 9 days of differentiation [1] [2] Direct evidence of improved specification of nephron progenitor cells, a critical step in kidney organoid formation.
Downstream Effect Increased efficiency in developing tubular kidney organoids [1] Leads to more robust and reproducible in vitro tissue models for research and drug screening.
Research Reagent Solutions

Table 2: Essential Materials for Epigenetic Priming and Kidney Organoid Differentiation

Item Function/Application Example(s)
hiPSC Lines Starting cellular material for differentiation. LUMCi004-C, TISSUi001-A, TISSUi007-A [2]
Basal Culture Medium Maintains hiPSC pluripotency prior to differentiation. mTeSRplus [2]
DMSO Epigenetic priming agent to enhance differentiation potential. Dimethyl Sulfoxide, 1-2% (v/v) [1] [2]
Extracellular Matrix Provides a physiological substrate for cell attachment and growth. Geltrex (1% solution) [2]
Dissociation Reagent Generates single-cell suspensions for seeding and analysis. Accutase [2]
Rho-associated kinase (ROCK) inhibitor Improves survival of single-cell seeded hiPSCs. Y-27632 [2]
Antibodies for Flow Cytometry Assessment of pluripotency surface and intracellular markers. TRA-1-60, TRA-1-81, SSEA3, SSEA4, SOX2, OCT4 [2]
Antibodies for Immunostaining Characterization of kidney organoid cell types. SIX2 (NPCs), PODXL (podocytes), LRP2 (proximal tubules), GATA3 (distal/collecting tubules) [2]
Experimental Workflow and Signaling Diagram

G Start Culture hiPSCs A DMSO Pre-treatment (1-2% for 24h) Start->A B Alters Epigenetic Landscape A->B C Changes in Gene Expression (OCT4, SOX2) B->C D Shift in Colony Morphology B->D E Induction of Kidney Differentiation Protocol C->E D->E F Enhanced SIX2+ Nephron Progenitor Formation E->F G Efficient Kidney Organoid Generation F->G

A Step-by-Step Protocol: Implementing DMSO Conditioning for Robust Kidney Organoid Differentiation

hiPSC Culture Maintenance and Preparation for Differentiation

Troubleshooting Guides

Common hiPSC Culture Issues and Solutions
Problem Possible Causes Recommended Solutions
Excessive differentiation (>20%) Old culture medium; overgrown colonies; prolonged time outside incubator [29] Use medium <2 weeks old; passage before overgrowth; limit time outside incubator to <15 min [29]
Poor cell attachment after passaging Over-confluent cultures; excessive pipetting; sensitive cell line [29] [30] Passage at ~85% confluency; reduce pipetting; use ROCK inhibitor (Y-27632) [29] [30]
Inconsistent cell aggregate size Incorrect passaging reagent incubation time or pipetting [29] Adjust ReLeSR incubation by 1-2 min; pipette gently for larger aggregates [29]
Differentiated cells detaching with colonies Over-incubation with passaging reagent [29] Reduce ReLeSR time by 1-2 min; lower temperature to 15-25°C [29]
Low yield after cryopreservation Suboptimal freezing/thawing protocols [31] [30] Use RevitaCell supplement; proper freezing medium with DMSO [31] [30]
hiPSC Quality Control Assessment
Quality Attribute Method of Assessment Acceptable Standard
Pluripotency Flow cytometry for TRA-1-60, TRA-1-81, SSEA3, SSEA4 [2] >90% positive expression [2]
Viability Trypan blue exclusion [31] >90% viability [31]
Morphology Microscopic examination [29] Large, compact colonies with dense centers [29]
Mycoplasma PCR testing [32] Negative

Frequently Asked Questions (FAQs)

General hiPSC Culture

Q: How often should I passage my hiPSC cultures? A: Passage hiPSCs when colonies are large and compact with dense centers, typically at ~85% confluency. Avoid overgrowth, which triggers differentiation [29] [30].

Q: What is the recommended splitting ratio for hiPSCs? A: This varies by cell line, but common ratios range from 1:10 to 1:20. Test different ratios to optimize for your specific line [2].

Q: Can I switch my hiPSCs from one culture medium to another? A: Yes, but passage cells manually or with EDTA when transitioning to the new system. Some lines may adapt better when thawed into their original medium before switching [30].

Preparation for Differentiation

Q: How does DMSO pretreatment improve kidney organoid differentiation? A: Treating hiPSCs with 1-2% DMSO for 24 hours before differentiation alters gene expression of pluripotency factors and the epigenetic landscape, enhancing expression of the key nephron progenitor marker SIX2 and improving tubular kidney organoid development [1] [2] [33].

Q: What cell density should I use when seeding hiPSCs for differentiation? A: Optimal density varies by cell line. For kidney organoid differentiation, researchers have used: 1×10^4 cells/cm² (LUMC line), 9×10^3 cells/cm² (HUMIMC101), and 7×10^3 cells/cm² (HUMIMC107) [2].

Q: Why is ROCK inhibitor used during passaging? A: ROCK inhibitor (Y-27632) increases cell survival after dissociation by inhibiting apoptosis, particularly important for single-cell passaging. Use at 10μM concentration [31] [30].

DMSO Pretreatment Protocol for Enhanced Kidney Organoid Differentiation

Background

DMSO pretreatment conditions hiPSCs for more efficient differentiation into nephron progenitors and kidney organoids. This approach addresses the challenge of generating complex structures with multiple cell types by priming hiPSCs through alterations in the epigenetic landscape and gene expression [1] [2].

Materials and Reagents
Reagent Function Concentration
mTeSR Plus medium hiPSC maintenance As recommended
Dimethyl sulfoxide (DMSO) Differentiation priming 1-2% (v/v)
Geltrex Extracellular matrix coating 1% solution
Y-27632 (ROCK inhibitor) Enhances cell survival 10μM
Accutase Cell dissociation As recommended
Step-by-Step Protocol
  • Culture hiPSCs on Geltrex-coated plates in mTeSR Plus medium until 85% confluent [2].
  • Harvest cells using Accutase incubated at 37°C for 10 minutes to create single-cell suspension [2].
  • Seed hiPSCs at optimized density for your cell line in mTeSR Plus supplemented with 10μM Y-27632 [2].
  • After 24 hours, replace medium with fresh mTeSR Plus [2].
  • On day 3, treat cells with mTeSR Plus supplemented with 1-2% DMSO for 24 hours [2].
  • Begin kidney organoid differentiation using established protocols (e.g., Morizane et al. 2017) [2].
Timing and Expected Outcomes
  • DMSO treatment: 24 hours
  • Key outcome measurement: Enhanced SIX2 expression (metanephric mesenchyme nephron progenitor marker) after 9 days of kidney organoid differentiation [2] [33]
  • Validation: Flow cytometry for pluripotency markers (OCT3/4, SOX2, TRA-1-60, TRA-1-81, SSEA3, SSEA4) pre- and post-DMSO treatment [2]

Experimental Workflow and Signaling Pathways

hiPSC Culture to Kidney Organoid Differentiation Workflow

Start hiPSC Culture mTeSR Plus Geltrex Coating Harvest Harvest with Accutase Single Cell Suspension Start->Harvest Seed Seed at Optimized Density + ROCK Inhibitor Harvest->Seed DMSO 24h DMSO Treatment (1-2%) Seed->DMSO Diff Kidney Organoid Differentiation DMSO->Diff Outcome Enhanced SIX2 Expression Improved Tubular Structures Diff->Outcome

DMSO Mechanism in Pluripotency and Differentiation

DMSO DMSO Treatment (1-2%, 24h) Mech1 Alters Epigenetic Landscape DMSO->Mech1 Mech2 Modifies Pluripotency Gene Expression DMSO->Mech2 Mech3 Changes Colony Morphology DMSO->Mech3 Effect1 G1 Cell Cycle Arrest via PI3K Pathway Mech1->Effect1 Mech2->Effect1 Effect2 Enhanced Differentiation Potential Mech3->Effect2 Effect1->Effect2 Outcome Improved Kidney Organoid Efficiency & SIX2+ NPCs Effect2->Outcome

Research Reagent Solutions

Essential Materials for hiPSC Culture and Differentiation
Category Specific Reagent Function Example Supplier
Culture Medium mTeSR Plus Feeder-free hiPSC maintenance STEMCELL Technologies
Extracellular Matrix Geltrex/Matrigel Coating substrate for cell attachment Gibco/Corning
Passaging Reagents Gentle Cell Dissociation Reagent Non-enzymatic cell detachment STEMCELL Technologies
Cryopreservation DMSO/KO Serum Replacement Cryoprotectant for cell freezing Sigma/Gibco
Differentiation Priming DMSO Enhances differentiation efficiency Sigma
Cell Survival Y-27632 (ROCK inhibitor) Reduces apoptosis after passaging Tocris

Troubleshooting Guide: DMSO Treatment in Kidney Organoid Differentiation

This guide addresses common challenges researchers face when using low-dose DMSO to enhance the differentiation of human induced pluripotent stem cells (hiPSCs) into kidney organoids.

Q1: Why is DMSO pretreatment used in kidney organoid differentiation, and what are the key mechanistic insights?

DMSO pretreatment is used to enhance the efficiency of kidney organoid differentiation by altering the hiPSC state to make it more responsive to differentiation cues. The key mechanistic insights are:

  • Cell Cycle Regulation: DMSO treatment halts cells in the G1 phase of the cell cycle by preventing the phosphorylation of the retinoblastoma (Rb) protein. This arrest is mediated through alterations in PI3K pathway signalling, which is crucial for regulating the early transitory states of hiPSCs toward differentiation [2].
  • Gene Expression and Epigenetics: Treatment with 1-2% DMSO affects the gene expression of pluripotent transcription factors and alters the epigenetic landscape of hiPSCs. This pre-conditions the cells, making them more amenable to differentiation [1] [2].
  • Macromolecular Changes: Even at low concentrations (0.5-1.5%), DMSO can induce gross molecular changes in cells, including alterations in protein secondary structure (increased β-sheet over α-helix) and a reduction in total nucleic acid content. These widespread changes can interfere with various cellular processes and may underpin its differentiation-enhancing effects [34].

Q2: My cells are showing signs of toxicity or reduced viability after DMSO treatment. What could be the cause?

While 1-2% DMSO is generally tolerated by many cell types, cytotoxicity can occur and is often cell line-specific and concentration-dependent.

  • Confirm Solvent Concentration: Recalculate your dilution to ensure the final concentration in the culture medium does not exceed 2% (v/v). Higher concentrations can lead to significant cytotoxicity [16] [35].
  • Check Solvent Purity: Always use high-quality, sterile DMSO of cell culture or molecular biology grade.
  • Review Exposure Time: The standard pretreatment duration is 24 hours. Prolonged exposure can increase the risk of adverse effects. Adhere strictly to the 24-hour treatment window before initiating the kidney organoid differentiation protocol [2].
  • Include Controls: Always include a solvent control (culture medium with the same concentration of DMSO but no other test compounds) to distinguish solvent-induced effects from those caused by your experimental conditions [35].

Table: Cytotoxicity Profile of DMSO Across Different Cell Types

Cell Type Safe Concentration (≤24h) Toxic Concentration (24h exposure) Observed Effects
hiPSCs (for differentiation) 1-2% >2% Alters pluripotency, enhances differentiation efficiency [2].
Various Cancer Cell Lines* 0.3125% >0.3125% - 5% Variable, cell-type dependent cytotoxicity; MCF-7 cells are particularly sensitive [16] [36].
RTgill-W1 Fish Cells <0.5% ≥0.5% Dose-dependent decline in cell viability; metabolic disruptions even at 0.1% [35].
Epithelial Colon Cancer Cells N/A 0.5% - 1.5% ~10% reduction in cell growth; not due to apoptosis [34].

*Data from HepG2, Huh7, HT29, SW480, MCF-7, and MDA-MB-231 cell lines [16].

Q3: The efficiency of my nephron progenitor differentiation is inconsistent after DMSO pretreatment. How can I optimize this?

Inconsistency can stem from variations in hiPSC culture or DMSO handling.

  • Standardize hiPSC Starting Population: Ensure your hiPSCs are healthy, have a high viability, and are in a "primed" state of pluripotency before starting the experiment. Use consistent seeding densities optimized for your specific hiPSC line [2].
  • Monitor Colony Morphology: Treating hiPSCs with 1-2% DMSO for 24 hours will affect colony morphology. Be familiar with the expected morphological changes in your cell line to serve as an initial quality check [2].
  • Validate with Pluripotency Markers: Use flow cytometry to assess the expression of key pluripotency markers (e.g., TRA-1-60, TRA-1-81, SSEA3, SSEA4, SOX2, OCT3/4) after the 24-hour DMSO treatment. This confirms the treatment has effectively altered the cellular state [2].
  • Quantify Differentiation Success: The key metric for success is the enhanced expression of the metanephric mesenchyme nephron progenitor marker, SIX2, after 9 days of kidney organoid differentiation. Use immunostaining or flow cytometry to quantitatively compare SIX2 levels in DMSO-treated versus untreated control organoids [1] [2].

Research Reagent Solutions

Table: Essential Materials for DMSO Pretreatment and Kidney Organoid Differentiation

Reagent / Material Function / Application Example / Catalog Note
Dimethyl Sulfoxide (DMSO) Solvent for pretreatment; alters hiPSC state to enhance differentiation. Use cell culture grade, sterile-filtered.
hiPSC Lines Starting cell material for generating kidney organoids. Lines such as LUMCi004-C, HUMIMC101, HUMIMC107 [2].
Geltrex Basement membrane matrix for coating culture plates. Provides a substrate for hiPSC attachment and growth.
mTeSRplus Medium Maintenance medium for hiPSC culture. Keeps hiPSCs in a pluripotent state prior to differentiation.
Accutase Enzyme for dissociating hiPSC colonies into a single-cell suspension. For accurate cell counting and seeding.
Y-27632 (ROCK inhibitor) Improves survival of hiPSCs after single-cell dissociation. Add to medium when passaging or seeding cells for experiments.
Antibodies for Flow Cytometry Characterizing pluripotency and differentiation markers. TRA-1-60, TRA-1-81, SSEA4, SOX2, OCT3/4 (pluripotency); SIX2 (nephron progenitor) [2].

Experimental Protocol: DMSO Pretreatment of hiPSCs for Enhanced Kidney Organoid Differentiation

This protocol is adapted from studies demonstrating that DMSO preconditioning improves the efficiency of generating kidney organoids [2].

  • Culture and Passage hiPSCs: Maintain hiPSC colonies on Geltrex-coated plates with mTeSRplus medium. Passage cells using gentle cell dissociation reagent or Accutase to maintain colonies.
  • Seed hiPSCs for Differentiation:
    • Harvest hiPSCs using Accutase to create a single-cell suspension.
    • Resuspend cells in mTeSRplus medium supplemented with 10 µM Y-27632 (ROCK inhibitor).
    • Seed cells onto Geltrex-coated plates at a density optimized for your hiPSC line (e.g., 1.0 × 10⁴ cells/cm² for LUMC lines).
  • DMSO Pretreatment:
    • Day 0: Seed cells.
    • Day 1: Replace medium with fresh mTeSRplus.
    • Day 2: Replace medium with mTeSRplus supplemented with the desired concentration of DMSO (e.g., 1% or 2% v/v). Incubate for 24 hours.
  • Initiate Kidney Organoid Differentiation: After the 24-hour DMSO treatment, remove the DMSO-containing medium. Wash the cells once with PBS and proceed with your standard kidney organoid differentiation protocol (e.g., the stepwise 2D monolayer-based protocol by Morizane et al.).

Signaling Pathway and Experimental Workflow

The following diagrams illustrate the proposed mechanism of DMSO action and the experimental workflow.

G DMSO DMSO Treatment (1-2%, 24h) PI3K Alters PI3K Signaling DMSO->PI3K Pluripotency Alters Pluripotency: - Gene Expression - Epigenetic Landscape DMSO->Pluripotency Rb Prevents Rb Phosphorylation PI3K->Rb G1_Arrest G1 Phase Cell Cycle Arrest Rb->G1_Arrest Outcome Enhanced Differentiation Efficiency to SIX2+ NPCs G1_Arrest->Outcome Pluripotency->Outcome

DMSO Mechanism: G1 Arrest & Pluripotency Alteration

G Start Culture & Maintain hiPSCs Seed Seed hiPSCs as Single Cells + ROCKi Start->Seed Treat 24h Treatment with DMSO (1-2%) in mTeSRplus Seed->Treat Diff Initiate Kidney Organoid Differentiation Protocol Treat->Diff Analyze Analyze Markers: - Day 0: Pluripotency (Flow) - Day 9: SIX2 (IF/Flow) Diff->Analyze

Workflow: DMSO Pretreatment & Differentiation

Integration with Established Kidney Organoid Protocols (e.g., Morizane et al.)

Core Concept: DMSO Conditioning for Enhanced Differentiation

What is DMSO conditioning, and how does it improve my kidney organoid differentiation? Dimethyl sulfoxide (DMSO) conditioning involves treating human induced pluripotent stem cells (hiPSCs) with low concentrations of DMSO (1-2%) for 24 hours prior to initiating kidney organoid differentiation. This pretreatment modifies the pluripotent state of hiPSCs, making them more responsive to differentiation signals and significantly enhancing the efficiency of generating nephron progenitor cells (NPCs) and subsequent kidney organoids [1] [2].

The primary mechanism involves DMSO-induced alterations in key cellular pathways. Research indicates that DMSO prevents the phosphorylation of retinoblastoma protein, arresting cells in the G1 phase of the cell cycle through modifications in PI3K pathway signaling. This cell cycle synchronization regulates early transitional states of hiPSCs toward differentiation. Additionally, DMSO treatment influences genes involved in cytoskeletal dynamics, cilium assembly, and cell adhesion—all critical processes during organogenesis [2].

Table: Key Effects of DMSO Conditioning on hiPSCs

Parameter Effect of DMSO Conditioning Significance for Kidney Organoid Differentiation
Cell Cycle Arrests cells in G1 phase via retinoblastoma phosphorylation prevention [2] Synchronizes cell population for more uniform differentiation response
Gene Expression Alters expression of pluripotency transcription factors (OCT3/4, SOX2) [2] Primes cells for exit from pluripotency and lineage commitment
Pathway Signaling Modifies PI3K pathway signaling [2] Regulates early transitional states toward differentiation
Cellular Processes Influences cytoskeletal dynamics, cilium assembly, cell adhesion [2] Enhances processes critical for morphogenesis and tissue organization
Epigenetic Landscape Modifies epigenetic state [2] Makes chromatin more accessible to kidney lineage transcription factors

Experimental Protocols

Detailed Methodology: DMSO Conditioning Integration

How do I technically implement DMSO conditioning into the Morizane protocol? Integrating DMSO conditioning requires modification of the initial stages of the established Morizane protocol. The specific steps are as follows [2]:

  • hiPSC Culture and Seeding: Maintain hiPSC colonies (e.g., LUMC, HUMIMC101, HUMIMC107 lines) on 1% Geltrex-coated plates with mTeSRplus medium. When ready for differentiation, create a single-cell suspension using Accutase and seed onto Geltrex-coated plates at optimized densities:

    • LUMC line: 1.0 × 10⁴ cells/cm²
    • HUMIMC101 line: 9.0 × 10³ cells/cm²
    • HUMIMC107 line: 7.0 × 10³ cells/cm² Use mTeSRplus supplemented with 10 µM Y-27632 (ROCK inhibitor) for the first 24 hours post-seeding.

  • DMSO Conditioning: On the third day of culture, replace the medium with mTeSRplus supplemented with either 1% or 2% (v/v) DMSO. Include a negative control group with no DMSO. Treat the cells for exactly 24 hours.

  • Protocol Transition: After 24 hours of DMSO exposure, completely remove the DMSO-containing medium. Wash the cells once with PBS and proceed immediately with the standard stepwise differentiation protocol as described by Morizane et al. (2017), beginning with primitive streak induction using CHIR99201 [2].

Workflow Visualization

The following diagram illustrates how DMSO conditioning is integrated into the established kidney organoid differentiation workflow:

G Start Culture hiPSCs A Seed hiPSCs for differentiation (Use line-specific densities) Start->A B Culture for 48 hours in mTeSRPlus + Y-27632 (first 24h) A->B C DMSO Conditioning 24h in mTeSRPlus + 1-2% DMSO B->C D Wash cells with PBS C->D E Begin Morizane Protocol Primitive Streak Induction (CHIR99201) D->E F Continue with subsequent steps (IM induction, NPC specification, etc.) E->F End Mature Kidney Organoids F->End

Troubleshooting Guide

FAQ: I am not observing the expected increase in SIX2+ progenitor cells after DMSO conditioning. What could be wrong?

Table: Troubleshooting Common Issues with DMSO Conditioning

Problem Potential Causes Solutions & Verification Methods
Poor NPC Yield • Incorrect hiPSC seeding density• Suboptimal DMSO concentration for your cell line• hiPSCs not in healthy, pluripotent state pre-differentiation • Optimize seeding density for your specific hiPSC line [2].• Titrate DMSO (test 0.5%, 1%, 1.5%, 2%) [2].• Check pluripotency markers (OCT4, SOX2, TRA-1-60) via flow cytometry before starting [2].
Increased Cell Death • DMSO concentration too high• DMSO not properly diluted, causing osmotic shock• Using industrial-grade DMSO with impurities • Ensure DMSO is high-quality, cell culture grade (>99.9% purity) [37] [38].• Always dilute DMSO thoroughly in pre-warmed medium before adding to cells.• Perform a live/dead assay (e.g., Calcein-AM/EthD-1) after conditioning to assess cytotoxicity [39].
High Batch-to-Batch Variability • Inconsistent hiPSC colony morphology pre-treatment• Variations in DMSO treatment timing• Spontaneous differentiation in starting hiPSC culture • Standardize the morphology and confluency of hiPSCs at the start of DMSO treatment [2].• Precisely time the 24-hour DMSO exposure.• Regularly karyotype and authenticate hiPSC lines. Use low-passage cells.
Off-Target Differentiation • DMSO pretreatment altering response to subsequent morphogens • Titrate CHIR99201 concentration after DMSO conditioning, as differentiation kinetics may be accelerated [40].• Analyze day 9 organoids for off-target markers (e.g., TUJ1 for neural, SOX17 for endoderm).

FAQ: Is DMSO safe to use at these concentrations, and are there any specific handling considerations? At low concentrations (1-2%), DMSO is generally considered safe for in vitro cell culture, but it requires careful handling [37]. A systematic review of adverse reactions concluded that most reactions are transient and mild, with a clear relationship between dose and adverse effects [37]. However, always use high-purity, cell culture-grade DMSO. Industrial-grade DMSO may contain harmful impurities that can be transported into cells, causing toxicity [38]. Be aware that DMSO is a potent penetrant and will rapidly absorb through the skin, so wear appropriate personal protective equipment (PPE) when handling.

Signaling Pathways and Mechanisms

How does DMSO mechanistically prime hiPSCs for more efficient kidney differentiation? DMSO conditioning exerts its effects through multimodal mechanisms that converge to lower the threshold for lineage specification. The key mechanistic insights are summarized in the diagram below:

G DMSO DMSO (1-2%) RB Inhibits RB Phosphorylation DMSO->RB PI3K Alters PI3K Pathway Signaling DMSO->PI3K Chromatin Modifies Epigenetic Landscape DMSO->Chromatin Cytoskeleton Affects Cytoskeletal Dynamics & Cell Adhesion DMSO->Cytoskeleton Pluripotency Alters Pluripotency Factor Expression (OCT4, SOX2) DMSO->Pluripotency CellCycle G1 Cell Cycle Arrest RB->CellCycle Outcome Primed State for Differentiation Enhanced Kidney Organoid Efficiency CellCycle->Outcome PI3K->Outcome Chromatin->Outcome Cytoskeleton->Outcome Pluripotency->Outcome

The synergy of these mechanisms—cell cycle synchronization, epigenetic modulation, and morphological priming—results in a hiPSC population that is more responsive to the directed differentiation signals of the kidney protocol, ultimately leading to enhanced expression of key markers like SIX2 in nephron progenitor cells and improved organoid morphology [1] [2].

Research Reagent Solutions

Table: Essential Materials for DMSO-Enhanced Kidney Organoid Differentiation

Reagent/Catalog Function in Protocol Specifications & Alternatives
Cell Culture-Grade DMSO Priming agent for hiPSCs; enhances differentiation potential. Must be >99.9% purity. Avoid industrial grade due to toxic impurities [37] [38].
hiPSC Lines Starting cell source for organoid generation. Protocols validated on LUMCi004-C, TISSUi001-A, TISSUi007-A lines [2].
mTeSRPlus Medium Maintenance of hiPSCs in pluripotent state pre-conditioning. Defined, feeder-free culture system.
Geltrex/Matrigel Extracellular matrix coating for 2D hiPSC culture and differentiation. Provides essential adhesion cues.
CHIR99201 (CHIR) GSK-3β inhibitor; used for primitive streak induction. Concentration and timing are critical and may require optimization post-DMSO [40].
FGF9 & Heparin Key growth factors for intermediate mesoderm and nephron progenitor induction. Works with CHIR to promote posterior IM fate [40].
Anti-SIX2 Antibody Validation of nephron progenitor cell population. Key readout for protocol success; efficiency should increase with DMSO conditioning [1] [2].
Ultra-Low Attachment Plates For 3D organoid formation from induced NPCs. Enables mass production of organoids in a reproducible format [40].

SIX2 is a homeodomain transcriptional regulator that defines a multipotent, self-renewing nephron progenitor population throughout kidney development [41]. These SIX2-expressing cells give rise to all the major cell types of the main body of the nephron, from the glomerular podocytes to the distal tubule [41]. In the context of kidney organoid differentiation, the emergence of SIX2+ progenitors represents a key milestone, indicating successful specification towards kidney lineages. Recent research has demonstrated that treatment with low-dose dimethyl sulfoxide (DMSO) can enhance the expression of SIX2 during kidney organoid differentiation, improving protocol efficiency and the development of tubular kidney organoids [1] [21]. This technical support center provides comprehensive guidance for tracking this crucial marker and troubleshooting common experimental challenges.

Frequently Asked Questions (FAQs)

Q1: What does SIX2 expression indicate in my kidney organoid differentiation experiment? SIX2 expression is a key marker of metanephric mesenchyme and identifies self-renewing nephron progenitor cells [41]. In your organoids, robust SIX2 expression after approximately 9 days of differentiation indicates successful specification of nephron progenitors capable of generating all segments of the main nephron body [1]. The presence of these progenitors is essential for generating properly segmented nephron structures.

Q2: How can I improve SIX2+ progenitor emergence in my organoid differentiations? Recent evidence suggests that treating human induced pluripotent stem cells (hiPSCs) with 1-2% DMSO prior to and during differentiation enhances SIX2 expression after 9 days of kidney organoid differentiation [1] [21]. This treatment affects the epigenetic landscape and pluripotency transcription factors, priming cells for more efficient nephron progenitor differentiation.

Q3: What are the common issues affecting SIX2+ progenitor generation and how can I address them? The table below summarizes frequent challenges and potential solutions:

Table: Troubleshooting Guide for SIX2+ Progenitor Generation

Problem Potential Causes Recommended Solutions
Low SIX2 expression Inefficient mesoderm patterning; suboptimal WNT activation; insufficient FGF signaling Optimize CHIR99021 concentration and timing; incorporate DMSO pre-treatment; validate FGF9 activity [1] [42]
High variability between differentiations Inconsistent hiPSC colony morphology; batch-to-batch reagent variation; passage number effects Standardize hiPSC colony size before differentiation; use freshly prepared small molecule inhibitors; monitor passage number effects [21]
Poor organoid formation after progenitor specification Inadequate 3D culture conditions; improper timing of dissociation Optimize Matrigel concentration; ensure proper reaggregation technique; confirm WNT activation timing [42]

Q4: Beyond immunostaining, what methods can I use to confirm authentic nephron progenitor identity? Functional validation is crucial. Consider these approaches:

  • Clonal analysis: Assess multipotency by determining if single cells can contribute to multiple nephron domains [41]
  • Self-renewal assays: Evaluate capacity for maintenance through serial passaging [42]
  • Transcriptional profiling: Perform scRNA-seq to confirm expression of other nephron progenitor markers (CITED1, WT1, OSR1, SAL11) [43]
  • Differentiation potential: Verify ability to form all nephron segments except collecting ducts [41]

Q5: How do I know if my SIX2+ cells are properly localized within the organoid? In developing kidneys, SIX2+ cells form a cap mesenchyme surrounding the ureteric epithelium [41]. In organoids, look for organized clusters of SIX2+ cells that exclude collecting duct markers (cytokeratin) and stromal markers [41]. Proper localization often correlates with improved tubular formation.

Experimental Protocols & Methodologies

DMSO-Enhanced Kidney Organoid Differentiation

This protocol modifies the stepwise 2D monolayer-based method developed by Morizane et al. (2017) with DMSO treatment to enhance SIX2+ progenitor emergence [1] [21].

Key Reagents and Materials: Table: Essential Research Reagents for DMSO-Enhanced Differentiation

Reagent/Cell Line Specification/Function
hiPSC Lines LUMCi004-C, TISSUi001-A, or TISSUi007-A with appropriate ethics approval [1]
Dimethyl Sulfoxide (DMSO) 1-2% in base medium; affects epigenetic landscape and pluripotency factors [1] [21]
CHIR99021 GSK3β inhibitor for WNT pathway activation; critical for progenitor specification [42]
FGF9 Maintains progenitor self-renewal and supports nephron formation [42]
Matrigel Provides 3D extracellular matrix environment for organoid formation

Detailed Protocol:

  • hiPSC Pre-treatment with DMSO (Days -3 to 0):

    • Culture hiPSCs in essential 8 medium supplemented with 1-2% DMSO
    • Monitor colony morphology changes indicative of altered pluripotency state
    • Refresh DMSO-containing medium daily [1] [21]

  • Directed Differentiation (Days 0-9):

    • Day 0: Initiate differentiation with CHIR99021 (typically 3-12μM) in basal medium
    • Maintain DMSO treatment during initial differentiation phase
    • Days 3-5: Transition to FGF9-containing medium to support progenitor expansion
    • Day 7-9: Assess SIX2 emergence via immunostaining or qPCR [1]

  • Organoid Formation (Days 9+):

    • Dissociate progenitor populations and transfer to 3D culture
    • Use Matrigel or similar matrices to support epithelial reorganization
    • Continue with nephron maturation protocols with timed WNT activation

Quantitative Assessment of SIX2+ Progenitors

Flow Cytometry Analysis:

  • Harvest cells at differentiation day 9 using gentle dissociation
  • Fix and permeabilize using standard intracellular staining protocols
  • Incubate with validated anti-SIX2 primary antibodies
  • Use appropriate fluorophore-conjugated secondary antibodies
  • Analyze using flow cytometry; expect 10-30% SIX2+ cells in optimized differentiations [42]

Immunofluorescence Staining:

  • Fix developing organoids in 4% PFA for 15-20 minutes
  • Permeabilize with 0.3% Triton X-100
  • Block with 5% normal serum matching secondary antibody host species
  • Incubate with anti-SIX2 primary antibody (1:100-1:500) overnight at 4°C
  • Use high-specificity secondary antibodies with minimal cross-reactivity
  • Counterstain with DAPI and image using confocal microscopy [41]

Data Presentation & Analysis

Table: Quantitative Markers of Successful SIX2+ Progenitor Specification

Parameter Baseline (No DMSO) With DMSO Treatment Assessment Method
SIX2+ Cell Population 5-15% 15-30% Flow cytometry at day 9 [1]
Nephron Tubule Formation Limited, discontinuous Enhanced, continuous tubules Immunofluorescence for tubular markers [1]
Organoid Size Variability High (≥40% CV) Reduced (≤25% CV) Morphometric analysis [21]
Co-expression with CITED1 <10% of SIX2+ cells 15-30% of SIX2+ cells Multiplex immunofluorescence [44]

Signaling Pathways and Molecular Regulation

The diagram below illustrates the key signaling pathways regulating SIX2+ nephron progenitor self-renewal and differentiation, and how DMSO treatment influences this process:

G DMSO DMSO Epigenetic Epigenetic DMSO->Epigenetic Pluripotency Pluripotency DMSO->Pluripotency SIX2_expression SIX2_expression Epigenetic->SIX2_expression Pluripotency->SIX2_expression FGF_signaling FGF_signaling FGF_signaling->SIX2_expression TGFb_signaling TGFb_signaling TGFb_signaling->SIX2_expression WNT_signaling WNT_signaling Differentiation Differentiation WNT_signaling->Differentiation SIX2_expression->WNT_signaling Inhibits Self_renewal Self_renewal SIX2_expression->Self_renewal Self_renewal->Differentiation Controlled Transition

DMSO Influences SIX2 Regulation Network

This schematic illustrates how DMSO treatment modulates the epigenetic landscape and pluripotency factors to enhance SIX2 expression, which maintains progenitor self-renewal by antagonizing pro-differentiation WNT signaling while being supported by FGF and TGFβ pathways [1] [42] [43].

Advanced Applications and Disease Modeling

Successfully generated SIX2+ nephron progenitor cells enable numerous downstream applications:

Disease Modeling:

  • Wilms Tumor: SIX2 remains active in Wilms tumor blastemal components, making these progenitors valuable for pediatric cancer modeling [44]
  • Polycystic Kidney Disease: Genome-edited NPC lines can model ADPKD mechanisms and screen anti-cystic compounds [42]
  • Congenital Anomalies: Study CAKUT-associated genetic variants during nephron formation [42]

Drug Screening:

  • Utilize scalable NPC cultures for high-throughput compound screening
  • Model nephrotoxicity and identify protective compounds [42]
  • Test novel therapeutics targeting kidney development and regeneration

Tracking SIX2+ nephron progenitor emergence provides a critical quality control metric in kidney organoid differentiation. The integration of DMSO treatment represents an innovative approach to enhance differentiation efficiency and organoid maturation. By implementing the troubleshooting guides, experimental protocols, and analytical methods outlined in this technical resource, researchers can significantly improve the reproducibility and quality of kidney organoid generation for both basic research and therapeutic applications.

Within the broader research on improving kidney organoid differentiation efficiency via DMSO treatment, the final and most critical step is the rigorous characterization of the resulting structures. This guide provides detailed troubleshooting and methodological support for researchers analyzing the tubular and glomerular compartments of kidney organoids, enabling the validation of protocol efficiency and the assessment of DMSO's impact on nephron progenitor commitment.

Frequently Asked Questions (FAQs)

Q1: What are the key markers for identifying glomerular and tubular structures in kidney organoids? A1: Glomerular structures are primarily identified by the presence of podocyte-specific markers such as podocalyxin (PODXL), nephrin (NPHS1), and WT1. These structures are typically negative for tubular markers like E-cadherin (ECAD) and Lotus Tetragonolobus Lectin (LTL). Conversely, proximal tubule-like structures are identified by LTL and megalin (LRP2) positivity, while distal tubule-like and loop of Henle-like structures express ECAD and GATA3 [45] [2].

Q2: My organoids show high variability in structure formation. What are the main sources of this variation? A2: High variability is a well-known challenge. Recent studies using multivariate models have identified that the culture approach, choice of iPSC line, experimental replication, and initial cell seeding number can explain 35-77% of the variability in the proportion of nephrin-positive (glomerular) and ECAD-positive (tubular) areas [46]. Implementing standardized, high-throughput methods can help control for this variability.

Q3: How does pretreatment with DMSO improve the final organoid quality? A3: Pretreating human induced pluripotent stem cells (hiPSCs) with low-dose (1-2%) Dimethyl Sulfoxide (DMSO) for 24 hours prior to differentiation affects the gene expression of pluripotent transcription factors and the epigenetic landscape. This preconditioning enhances the expression of SIX2, a key marker for metanephric mesenchyme nephron progenitor cells (NPCs), after 9 days of kidney organoid differentiation. This priming effect leads to more efficient development of tubular kidney organoids [1] [2].

Q4: What analytical methods are best for quantifying structure composition in organoids? A4: A combination of techniques is most effective:

  • Immunofluorescence and Confocal Microscopy: For visualizing and confirming the spatial organization of segmented nephron components [45].
  • Quantitative High-Content Screening: Allows for the quantification of marker-positive areas (e.g., nephrin and ECAD) across many organoids, providing robust statistical power [46].
  • Single-Cell RNA Sequencing (scRNA-seq): Provides deep insight into the transcriptional variety and cellular composition, allowing for the identification and proportioning of distinct cell populations like podocyte-like, tubule-like, and endothelial-like cells [45].

Troubleshooting Guides

Problem: Low Yield of SIX2-Positive Nephron Progenitor Cells

Potential Cause: Inefficient priming of hiPSCs towards a differentiation-competent state. Solution:

  • DMSO Preconditioning: Implement a 24-hour pretreatment of hiPSCs with 1-2% v/v DMSO in mTeSRplus medium prior to the initiation of the kidney organoid differentiation protocol [2].
  • Verification: Use flow cytometry or qPCR to confirm the enhanced expression of SIX2 at the nephron progenitor stage (around day 9) as an indicator of improved protocol efficiency [1].

Problem: High Inter-Organoid Variability in Size and Cell Composition

Potential Cause: Inconsistent initial aggregate formation using traditional methods like colony lifting. Solution:

  • Standardized Reaggregation: Dissociate hiPSCs or committed progenitor cells into a single-cell suspension and seed them in low-adhesion U-bottom 96-well plates at a defined cell number (e.g., 2,000-8,000 cells per well). Centrifugation forces the formation of uniformly sized spheroids [47] [45].
  • Optimized Seeding Density: Studies have shown that initial spheroids formed from 500 to 8,000 PIM-committed cells develop a higher number of PAX2+LHX1+ renal vesicle structures and show a greater degree of maturation compared to larger aggregates [45].

Problem: Poorly Segmented or Immature Tubular and Glomerular Structures

Potential Cause: Suboptimal culture conditions during later differentiation stages. Solution:

  • Free-Floating Culture: After the initial spheroid formation, maintain organoids in free-floating culture conditions to promote self-organization and maturation [45].
  • Structure Validation: Systematically confirm the segmentation of nephron structures using immunofluorescence for compartment-specific markers (see Table 1 below).

Experimental Protocols & Data Presentation

Key Protocol: Immunofluorescence Analysis for Structural Characterization

This protocol is used to validate the presence and organization of glomerular and tubular structures in day 14-16 kidney organoids [45] [2].

  • Fixation: Fix mature organoids in 4% paraformaldehyde (PFA) for 30 minutes to 1 hour at 4°C.
  • Permeabilization and Blocking: Permeabilize with 0.1-0.5% Triton X-100 and block with 2-5% serum (e.g., donkey or goat) for 1 hour.
  • Primary Antibody Staining: Incubate with primary antibodies diluted in blocking buffer overnight at 4°C. Key antibody combinations include:
    • Glomeruli: PODXL + WT1 + (Optional: Nephrin)
    • Proximal Tubules: LTL + (Optional: LRP2)
    • Distal Tubules/Loops of Henle: ECAD + GATA3
  • Secondary Antibody Staining: Incubate with fluorophore-conjugated secondary antibodies for 2 hours at room temperature. Include DAPI for nuclear counterstaining.
  • Imaging: Acquire high-resolution z-stack images using a confocal microscope.
  • Quantification: Use image analysis software (e.g., ImageJ, CellProfiler) to quantify the positive area percentage for each marker.

Quantitative Data on Organoid Structure Composition

Table 1: Key Protein Markers for Characterizing Kidney Organoid Structures

Nephron Compartment Key Markers Function/Characterization
Glomerular / Podocyte PODXL, Nephrin, WT1, TCF21, NPHS2 Identifies podocyte-like cells and primitive glomeruli; PODXL+CD31−ECAD− [45] [2]
Proximal Tubule LTL, LRP2 (Megalin) Labels proximal tubule-like segments; LTL+PODXL−WT1− [45] [2]
Distal Tubule / Loop of Henle ECAD, GATA3 Identifies distal tubule and loop of Henle-like structures; ECAD+PODXL−CD31− [45] [2]
Nephron Progenitor SIX2, PAX2 Marks metanephric mesenchyme nephron progenitor cells; critical for assessing DMSO preconditioning efficacy [1] [2]

Table 2: Impact of Culture Conditions on Structure Variability (Based on High-Content Screening)

Experimental Factor Impact on Nephrin+ (Glomerular) Area Impact on ECAD+ (Tubular) Area
Culture Approach Significant association with development [46] Significant association with development [46]
iPSC Line Used Significant association with development [46] Significant association with development [46]
Initial Cell Number Explains 35-77% of variability when modeled with other factors [46] Explains 35-77% of variability when modeled with other factors [46]

Workflow Diagram for Organoid Characterization

The following diagram illustrates the integrated workflow from stem cell preconditioning to the final quantitative analysis of kidney organoids.

Start hiPSC Culture Precond DMSO Preconditioning (1-2% for 24h) Start->Precond Diff Directed Differentiation to Intermediate Mesoderm Precond->Diff Agg Standardized 3D Aggregation (2,000-8,000 cells/well) Diff->Agg Culture Free-Floating Culture (Day 7 to Day 16) Agg->Culture Harvest Harvest Mature Organoids (Day 14-16) Culture->Harvest IF Immunofluorescence Staining & Confocal Imaging Harvest->IF Quant Quantitative Analysis (High-Content Screening) IF->Quant Seq scRNA-seq Validation Quant->Seq Optional

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents for Kidney Organoid Characterization

Reagent / Material Function in Characterization Example Usage
Anti-PODXL Antibody Labels podocytes in glomerular structures IF staining of day-16 organoids to visualize glomeruli [45]
Anti-Nephrin (NPHS1) Antibody Specific marker for podocyte slit diaphragms Confirm maturation of glomerular structures [45]
LTL (Lotus Tetragonolobus Lectin) Binds to proximal tubule epithelial cells IF staining to identify and quantify proximal tubules [46] [45]
Anti-ECAD (E-Cadherin) Antibody Marks distal tubule and loop of Henle cells IF staining to distinguish tubular segments [46] [45]
Anti-SIX2 Antibody Key transcription factor for nephron progenitors Assess differentiation efficiency after DMSO pretreatment [1] [2]
V-bottom 96-well Plates For generating uniformly sized organoids Standardized reaggregation of cells at the start of 3D culture [47] [45]
Matrigel / Geltrex Extracellular matrix for coating culture vessels Provides a substrate for initial 2D cell culture and differentiation [46] [2]
ROCK Inhibitor (Y-27632) Enhances cell survival after dissociation Added when passaging hiPSCs or creating single-cell suspensions for aggregation [46] [2]

Fine-Tuning Your Differentiation: Critical Parameters and Solutions for Common Challenges

Cell Line Variability and Seeding Density Optimization

Frequently Asked Questions (FAQs)

Q1: How does cell line stability impact long-term kidney organoid research? Cell line stability is the ability of cultured cells to maintain their genetic and phenotypic characteristics over extended passages. In kidney organoid research, instability can lead to genetic drift, where spontaneous mutations accumulate, altering cell behavior and differentiation efficiency. This can manifest as inconsistent generation of key progenitor cells, like SIX2+ nephron progenitors, directly compromising the reproducibility and quality of your organoids. [48]

Q2: What are the primary factors that contribute to cell line variability in hiPSC cultures? Several factors can introduce variability in hiPSC cultures, which is a critical consideration for differentiation protocols:

  • Genetic Drift: The accumulation of spontaneous mutations over prolonged passages. [48]
  • Epigenetic Changes: Shifts in gene expression patterns without DNA sequence modification. [48]
  • Culture Conditions: Variations in pH, temperature, oxygen levels, and shear stress can create selective pressures. [48]
  • Passage Number: Higher passage frequencies increase the risk of heterogeneity. [48]
  • Colony Morphology: Changes in physical structure, which can be influenced by treatments like DMSO, may reflect the differentiation potential of the cells. [1] [33]

Q3: Why is seeding density critical for efficient kidney organoid differentiation? While the search results do not provide an explicit quantitative optimum for kidney organoid seeding density, they underscore its fundamental importance. The initial cell concentration is a key experimental parameter; both excessively low and high densities can negatively impact culture growth and protocol efficiency. [49] Optimizing this parameter is therefore essential for achieving robust and reproducible differentiation.

Q4: How can I monitor and control cell line stability in my experiments? Implementing routine monitoring practices is essential for reliable research:

  • Authentication: Use Short Tandem Repeat (STR) profiling to confirm cell identity. [48]
  • Karyotyping: Detect chromosomal abnormalities. [48]
  • Phenotypic Analysis: Perform protein (e.g., immunofluorescence for SIX2) and mRNA expression analysis to identify deviations. [48]
  • Bank Management: Maintain frozen master and working cell banks at early passages to serve as a genetic reference and allow for culture renewal. [48]

Troubleshooting Guides

Problem: Low Efficiency in Nephron Progenitor Generation

Potential Causes and Solutions:

  • Cause: Suboptimal hiPSC Pre-Conditioning

    • Solution: Consider pre-treating hiPSCs with a low dose (1-2%) of Dimethyl Sulfoxide (DMSO) for 48 hours before initiating differentiation. This treatment has been shown to reshape the epigenetic landscape and enhance the expression of the key nephron progenitor marker SIX2. [1] [33] [15]

  • Cause: Inconsistent Culture Conditions

    • Solution: Standardize culture protocols. Use consistent media formulations and reagents, and employ automated or closed systems where possible to minimize environmental fluctuations in pH, temperature, and CO2. [48]

  • Cause: High Passage Number or Cell Line Instability

    • Solution: Limit the passage number of your hiPSCs and regularly return to low-passage frozen seed stocks. Routinely verify the identity and pluripotency of your cell lines. [48]
Problem: High Off-Target Cell Populations in Organoids

Potential Causes and Solutions:

  • Cause: Inefficient Differentiation Protocol
    • Solution: Refine differentiation cues. Single-cell transcriptomics has identified that up to 20% of cells in some kidney organoids can be non-renal (e.g., neuronal, muscle). Incorporating synthetic hydrogels with tailored biochemical and biophysical properties can provide more directed control over cell fate and reduce off-target populations. [3]
Quantitative Data for Kidney Organoid Differentiation Enhancement with DMSO

The following table summarizes key experimental data from a study investigating DMSO's effect on differentiation efficiency.

Table 1: Summary of DMSO Treatment Effects on hiPSC Differentiation [1] [33]

Parameter Control Condition (No DMSO) Experimental Condition (1-2% DMSO) Observation Method
hiPSC Colony Morphology Standard primed pluripotent state Altered, reshaped morphology Microscopy
Epigenetic Landscape Baseline state Modified Epigenetic analysis
SIX2+ Nephron Progenitor Generation Baseline efficiency Significantly enhanced Immunostaining / qPCR
Differentiation Protocol Efficiency Standard efficiency Improved toward tubular kidney organoids Organoid structural analysis

Experimental Protocols

Detailed Methodology: DMSO Pre-Conditioning for Enhanced Kidney Organoid Differentiation

This protocol is adapted from research by Kearney et al. (2025) for enhancing the differentiation of hiPSCs into kidney organoids. [1] [33]

1. Aim: To precondition hiPSCs with low-dose DMSO to increase the efficiency of differentiation into SIX2-positive nephron progenitor cells and subsequent kidney organoid formation.

2. Key Research Reagent Solutions

Item Function in the Protocol
Human induced Pluripotent Stem Cells (hiPSCs) The starting cell line with primed pluripotency, capable of differentiating into any adult cell type.
Dimethyl Sulfoxide (DMSO) A chemical treatment agent used to alter the gene expression of pluripotency factors, the epigenetic landscape, and colony morphology of hiPSCs.
Nephron Progenitor Marker SIX2 A key transcription factor used as a readout for successful differentiation into metanephric mesenchyme.
Stepwise 2D Monolayer Protocol The base kidney organoid differentiation method, as developed by Morizane et al. (2017), upon which the DMSO treatment is applied.

3. Procedure:

  • Step 1: Culture hiPSCs to an appropriate confluence in your standard maintenance medium.
  • Step 2: Pre-conditioning: Treat the hiPSCs with a culture medium supplemented with 1-2% (v/v) DMSO for a period of 48 hours. [1] [33]
  • Step 3: Differentiation Initiation: Following the DMSO pretreatment, initiate the standard stepwise 2D monolayer-based kidney organoid differentiation protocol. [1] [33]
  • Step 4: Analysis: After 9 days of differentiation, analyze the cultures for the presence of SIX2-positive nephron progenitors. The DMSO-treated conditions are expected to show a significant enhancement in marker expression compared to untreated controls. [1] [33]

Experimental Workflow and Signaling Diagrams

G Start Culture hiPSCs PreCondition Pre-condition with 1-2% DMSO for 48h Start->PreCondition DiffProtocol Initiate Kidney Organoid Differentiation Protocol PreCondition->DiffProtocol Outcome Analysis at Day 9 DiffProtocol->Outcome Result Enhanced SIX2+ Nephron Progenitor Generation Outcome->Result

DMSO Pre-conditioning Workflow

G DMSO DMSO Treatment Epigenetic Altered Epigenetic Landscape DMSO->Epigenetic Morphology Reshaped hiPSC Colony Morphology DMSO->Morphology GeneExp Altered Gene Expression of Pluripotency Factors DMSO->GeneExp Outcome Enhanced Differentiation Efficiency into SIX2+ Cells Epigenetic->Outcome Morphology->Outcome GeneExp->Outcome

DMSO Mechanism of Action

Dimethyl sulfoxide (DMSO) serves as a critical solvent and differentiating agent in biomedical research, particularly in the emerging field of kidney organoid differentiation. While traditionally used as a vehicle for water-insoluble compounds, recent investigations have revealed that low-dose DMSO can significantly enhance the efficiency of nephron progenitor and kidney organoid differentiation from human induced pluripotent stem cells (hiPSCs). This technical resource center addresses the precise balance required to harness DMSO's beneficial effects while mitigating its cytotoxic potential, providing essential troubleshooting guidance for researchers working to improve kidney organoid differentiation protocols.

DMSO Concentration Guidelines: Efficacy vs. Toxicity

Quantitative Toxicity Thresholds Across Cell Models

The cytotoxic effects of DMSO vary significantly across cell types and exposure conditions. The table below summarizes key toxicity findings from recent studies to guide experimental design.

Table 1: DMSO Cytotoxicity Profiles Across Experimental Models

Cell/Model Type Safe Concentration (≤20% viability reduction) Toxic Concentration (≥30% viability reduction) Key Findings Citation
RTgill-W1 fish cells <0.5% 0.5% and higher Metabolic disruptions detected even at 0.1%; ROS increase at 4% [35]
Cancer cell lines (HepG2, Huh7, HT29, SW480, MDA-MB-231) 0.3125% Variable by cell type Minimal cytotoxicity at 0.3125% except in MCF-7 cells [16]
RA fibroblast-like synoviocytes <0.05% 0.1% and higher ≈25% cell death at 0.5% after 24h; caspase-3 cleavage at 5% [50]
Prostate cancer cells (22Rv1, C4-2B) 0.1-1% 2.5% (≈20% cytotoxicity at 96h) Significant migration inhibition at 1.0% and 2.5% [51]
hiPSCs (kidney organoid differentiation) 1-2% Not reported Enhanced SIX2 expression and tubular organoid development [1]

Metabolic and Functional Impacts of DMSO

Beyond direct cytotoxicity, DMSO induces significant metabolic alterations even at low concentrations:

  • Metabolic Pathway Disruption: A 2025 study demonstrated that DMSO exposure (0.1-8%) in RTgill-W1 cells significantly impacted 41 metabolic pathways across five functional groups: amino acid metabolism, carbohydrate metabolism, lipid metabolism, vitamin and co-factor metabolism, and nucleotide metabolism [35].

  • Oxidative Stress: Significant increases in reactive oxygen species (ROS) were observed at DMSO concentrations of 4% and higher, indicating elevated oxidative stress contributing to cytotoxicity [35].

  • Gene Expression Modulation: In hiPSCs, DMSO treatment at 1-2% affects gene expression of pluripotent transcription factors, the epigenetic landscape, and colony morphology, ultimately enhancing expression of the key metanephric mesenchyme nephron progenitor marker SIX2 after 9 days of kidney organoid differentiation [1] [21].

Experimental Protocols for Kidney Organoid Research

DMSO Conditioning Protocol for Enhanced Kidney Organoid Differentiation

Table 2: Step-by-Step DMSO Conditioning Protocol

Step Procedure Duration Critical Parameters
hiPSC Culture Maintain hiPSCs in primed pluripotency state Pre-conditioning Use characterized hiPSC lines (e.g., LUMCi004-C, TISSUi001-A)
DMSO Treatment Add 1-2% DMSO to culture medium 24-48 hours Use high-purity, sterile DMSO; maintain consistent concentration
Kidney Differentiation Initiate stepwise 2D monolayer protocol (Morizane et al. 2017) 9 days for progenitor assessment Monitor SIX2 expression as key efficiency marker
Organoid Maturation Transfer to 3D culture conditions 10-21 days Assess tubular structure formation and complexity

G hiPSC Human iPSCs (Primed State) DMSO DMSO Conditioning (1-2%) hiPSC->DMSO Changes Epigenetic Modifications Gene Expression Changes Colony Morphology Alterations DMSO->Changes Differentiation Kidney Organoid Differentiation (Morizane Protocol) Changes->Differentiation Progenitor Enhanced Nephron Progenitors (SIX2 Expression) Differentiation->Progenitor Organoid Tubular Kidney Organoids Progenitor->Organoid

Figure 1: DMSO Conditioning Workflow for Enhanced Kidney Organoid Differentiation

Cytotoxicity Assessment Protocols

MTT Viability Assay Protocol (Adapted from multiple sources [16] [51] [50]):

  • Cell Seeding: Plate cells at optimized density (2000 cells/well for 96-well plates determined optimal for multiple cancer cell lines) and allow adherence for 24 hours [16].

  • DMSO Treatment: Prepare DMSO dilutions in culture media to achieve final concentrations ranging from 0.05-5%. Include solvent-free controls.

  • Exposure and Incubation: Replace culture medium with DMSO-containing media and incubate for 24-96 hours depending on experimental design.

  • MTT Application: Add 10μL MTT reagent (5 mg/mL) per well and incubate for 3-4 hours at 37°C to allow formazan crystal formation.

  • Solubilization and Measurement: Dissolve crystals in 100% DMSO and measure absorbance at 540-570 nm using a plate reader [51].

  • Data Analysis: Calculate cell viability relative to untreated controls. Apply the ISO 10993-5:2009 standard, which specifies that a reduction in cell viability exceeding 30% relative to control indicates cytotoxicity [16].

Troubleshooting Guides and FAQs

Frequently Asked Questions

Q: What is the maximum safe DMSO concentration for kidney organoid differentiation? A: The optimal window for kidney organoid differentiation efficiency is 1-2% DMSO for hiPSC preconditioning [1] [21]. However, comprehensive solvent controls must be included at matching concentrations as metabolic disruptions have been detected at concentrations as low as 0.1% in other cell models [35].

Q: How does DMSO enhance kidney organoid differentiation? A: DMSO conditioning affects gene expression of pluripotent transcription factors, modifies the epigenetic landscape, and alters hiPSC colony morphology. These changes prime cells for more efficient differentiation toward nephron progenitors, particularly enhancing expression of SIX2, a critical metanephric mesenchyme marker [1] [21].

Q: What solvent alternatives exist if DMSO toxicity is concerning for my specific cell type? A: Current research continues to prioritize DMSO for its unique differentiation-enhancing properties in kidney organoid formation. However, researchers should consider empirical testing of lower concentrations (0.5-1%) or exploring staggered exposure protocols to mitigate toxicity while maintaining efficacy [35] [51].

Q: How should I design appropriate solvent controls for kidney organoid experiments? A: Always include vehicle controls containing the same DMSO concentration used in experimental conditions. For kidney organoid differentiation using 1-2% DMSO, controls should contain exactly 1-2% DMSO without test compounds to distinguish solvent-induced effects from treatment-specific outcomes [35].

Table 3: Troubleshooting DMSO-Related Experimental Problems

Problem Potential Causes Solutions Preventive Measures
High background cytotoxicity DMSO concentration too high for specific cell type Perform cell-specific cytotoxicity screening; reduce concentration Use concentrations <0.1% for sensitive primary cells [50]
Inconsistent differentiation outcomes DMSO concentration variability; improper solvent controls Standardize DMSO source and preparation methods Include matched solvent controls in all experiments [35]
Reduced organoid formation efficiency DMSO exposure timing or duration suboptimal Optimize pretreatment duration (24-48h); test differentiation competence Validate pluripotency markers post-DMSO pretreatment [1]
Metabolic confounding effects DMSO-induced pathway alterations interfering with readouts Conduct metabolomic profiling; adjust interpretation Consider DMSO's impact on 41+ metabolic pathways [35]

The Scientist's Toolkit: Essential Research Reagents

Table 4: Key Research Reagents for DMSO-Based Kidney Organoid Research

Reagent/Cell Line Function/Application Specifications/Considerations Source/Reference
hiPSC Lines Differentiation starting material Use ethically approved lines (e.g., LUMCi004-C, TISSUi001-A) [1]
High-Purity DMSO Solvent and differentiation enhancer Sterile, cell culture tested; aliquot to prevent oxidation Various commercial sources
MTT Assay Kit Cytotoxicity assessment Optimize incubation time (3-4h) and cell density (2000 cells/well) [16]
SIX2 Antibodies Nephron progenitor validation Key marker for differentiation efficiency assessment [1] [21]
RPMI-1640 Medium Cell culture base Supplement with FBS or CS-FBS for specific applications [51]

Molecular Mechanisms of DMSO Action

G DMSO DMSO Exposure CellularEffects Cellular Effects DMSO->CellularEffects Metabolic Metabolic Disruptions 41 pathways affected CellularEffects->Metabolic Genetic Epigenetic & Gene Expression Changes CellularEffects->Genetic Oxidative Oxidative Stress ROS Production CellularEffects->Oxidative Outcomes Functional Outcomes Metabolic->Outcomes Genetic->Outcomes Oxidative->Outcomes Efficacy Differentiation Efficacy Enhanced SIX2 Expression Outcomes->Efficacy Toxicity Cytotoxicity Reduced Viability Outcomes->Toxicity

Figure 2: Dual Pathways of DMSO Efficacy and Toxicity

Understanding these mechanistic pathways is essential for optimizing the critical window of DMSO concentration. The beneficial effects on differentiation occur through epigenetic and gene expression modifications, while toxicity manifests through metabolic disruption and oxidative stress pathways [35] [1].

The critical window for DMSO concentration in kidney organoid research represents a precise balance between differentiation enhancement and cytotoxicity avoidance. Based on current evidence, the following best practices are recommended:

  • Empirical Optimization: Always conduct cell-specific cytotoxicity assays to establish safe DMSO thresholds for your specific experimental system.

  • Comprehensive Controls: Include solvent controls matched exactly to experimental DMSO concentrations to distinguish solvent effects from treatment outcomes.

  • Metabolic Awareness: Consider DMSO's extensive impact on metabolic pathways when interpreting omics data or metabolic readouts.

  • Differentiation-Specific Guidelines: For kidney organoid differentiation, the 1-2% DMSO conditioning window shows efficacy, but requires rigorous validation against control organoids without DMSO pretreatment.

The ongoing refinement of DMSO utilization protocols will continue to enhance the reproducibility and efficiency of kidney organoid generation, advancing disease modeling and drug screening applications.

Addressing Off-Target Cell Populations and Incomplete Differentiation

Troubleshooting Guide: FAQs on DMSO Treatment for Kidney Organoid Differentiation

Q1: What is the primary benefit of using DMSO pretreatment in kidney organoid differentiation?

DMSO pretreatment enhances the efficiency of kidney organoid differentiation by priming human induced pluripotent stem cells (hiPSCs). Treatment with low-dose (1-2%) DMSO for 24 hours before differentiation affects the expression of pluripotency transcription factors and the epigenetic landscape, making hiPSCs more amenable to differentiation. This pretreatment specifically boosts the expression of SIX2, a critical marker for metanephric mesenchyme nephron progenitor cells (NPCs), leading to more efficient development of tubular kidney organoids [2] [1].

Q2: How can I minimize off-target cell populations in my kidney organoids?

The persistence of off-target cell populations is a common challenge in prolonged organoid culture [2]. To address this:

  • Optimize Differentiation Timing: Focus on harvesting organoids at earlier time points when target cell populations, like SIX2-positive nephron progenitors, peak (around day 9 of differentiation with DMSO pretreatment) [2].
  • Implement Signaling Pathway Modulation: Recent research indicates that abnormal early cell states in organoids contribute to incomplete maturation. Transient inhibition of the PI3K signaling pathway during early nephrogenesis can help direct differentiation toward more authentic proximal tubule precursors by activating Notch signaling, thereby reducing off-target fates [52].
  • Include Proper Solvent Controls: DMSO itself can have widespread biological effects. Always include vehicle control groups treated with the same concentration of DMSO used in your experiments to distinguish true differentiation effects from solvent-induced artifacts [35] [53].

Q3: Why does my protocol yield kidney organoids with immature proximal tubules, and how can DMSO help?

Current organoid protocols often generate proximal tubule cells with low expression of key functional genes and solute carriers, indicating incomplete maturation [52]. While DMSO pretreatment improves the efficiency of generating nephron progenitors, further maturation may require combined approaches. DMSO acts by altering the "primed state" of hiPSCs, potentially making them more responsive to subsequent differentiation signals. For proximal tubule maturity, combining DMSO pretreatment with strategies like PI3K inhibition has been shown to promote a HNF4A+ proximal precursor state, which is crucial for developing functional transporters [52].

Q4: Are there any concerns about using DMSO as a solvent in my differentiation experiments?

Yes. While DMSO can enhance differentiation, it is not biologically inert and can cause off-target effects that must be controlled for.

  • Cellular Metabolism: Even low concentrations of DMSO (as low as 0.1%) can cause widespread metabolic disruptions, affecting amino acid, carbohydrate, and lipid metabolism [35].
  • Signaling Networks: In other cell models, ultra-low doses of DMSO have been shown to heterogeneously affect the expression and activation of hundreds of signaling proteins and kinases [54] [55].
  • Gene Expression and Epigenetics: Exposure to 0.1% DMSO can alter the transcriptome and DNA methylation profiles in certain cell types, indicating a potential impact on the epigenetic landscape [53].

Therefore, it is critical to use the lowest effective concentration and include meticulous solvent controls in all experiments.

Table 1: Effects of DMSO Pretreatment on hiPSCs and Kidney Organoid Differentiation
Parameter Investigated Experimental Finding Concentration Used Exposure Time Significance
SIX2 Nephron Progenitor Marker Enhanced expression after 9 days of differentiation [2] 1-2% 24 hours Indicates improved nephron progenitor population
hiPSC Pluripotency State Affected gene expression of pluripotency factors & colony morphology [2] 1-2% 24 hours Primes cells for differentiation
Cytotoxicity (in RTgill-W1 cells) Dose-dependent decline in cell viability [35] 0.5% and higher 24 hours Highlights concentration-dependent toxicity
Reactive Oxygen Species (ROS) Significant increase in ROS levels [35] 4% and higher 24 hours Induces oxidative stress at higher concentrations
Metabolic Pathway Disruption Altered levels of metabolites; significant impact on 41 pathways [35] 0.1% and higher 24 hours Confirms profound metabolic effects even at low doses
Table 2: Key Research Reagent Solutions for DMSO-Enhanced Kidney Organoid Differentiation
Reagent / Material Function in Protocol Example from Literature
hiPSC Lines Starting cell population for organoid differentiation LUMC0031iCTRL08; HUMIMC101; HUMIMC107 [2]
mTeSRPlus Medium Maintenance medium for hiPSC culture [2] Used for routine hiPSC culture pre-differentiation
Geltrex Extracellular matrix coating for cell culture plates Used at 1% solution to coat plates for hiPSC seeding [2]
Accutase Enzyme for cell dissociation to create single-cell suspensions Used for passaging hiPSCs and preparing cells for flow cytometry [2]
Y-27632 (ROCK inhibitor) Improves survival of dissociated hiPSCs Supplemented in medium during hiPSC seeding post-dissociation [2]
DMSO (Cell Culture Grade) Priming agent to enhance differentiation efficiency Used at 1-2% v/v in mTeSRPlus for 24 hours pre-differentiation [2]

Detailed Experimental Protocol: DMSO Priming for Kidney Organoids

The following methodology is adapted from the study by Kearney et al. (2025) [2].

Workflow: DMSO Priming and Kidney Organoid Differentiation

G Start Culture hiPSCs on Geltrex A Dissociate with Accutase Start->A B Seed single-cell suspension with Y-27632 A->B C 24h: Change to mTeSRPlus media B->C D DMSO Pretreatment (24 hours with 1-2% DMSO) C->D E Initiate Kidney Organoid Differentiation Protocol (e.g., Morizane et al.) D->E

1. hiPSC Culture Maintenance:

  • Maintain hiPSC colonies (e.g., LUMC0031iCTRL08, HUMIMC101, HUMIMC107) on cell culture plates coated with 1% Geltrex using mTeSRPlus medium.
  • Passage cells once colonies have rounded edges using gentle cell dissociation reagent. Gently break up colonies by pipetting and reseed at a splitting ratio of approximately 1:10 [2].

2. Seeding hiPSCs for Differentiation:

  • Add 1 mL of Accutase to a well of hiPSCs and incubate at 37°C for 10 minutes to create a single-cell suspension.
  • Resuspend the cells in mTeSRPlus medium supplemented with 10 µM Y-27632 (a ROCK inhibitor).
  • Seed the cells onto Geltrex-coated plates at a density optimized for your hiPSC line (e.g., 1.0 x 10⁴ cells/cm² for the LUMC line) [2].

3. DMSO Pretreatment:

  • On the third day of culture, replace the medium with mTeSRPlus medium supplemented with 1% or 2% (v/v) DMSO.
  • Incubate the cells for 24 hours. An untreated control group is essential for comparison [2].

4. Initiating Differentiation:

  • After the 24-hour DMSO treatment, remove the DMSO-containing medium.
  • Proceed with a stepwise kidney organoid differentiation protocol, such as the 2D monolayer-based method developed by Morizane et al. (2017) [2].

Key Analysis:

  • To assess the efficiency of nephron progenitor formation, evaluate the expression of the marker SIX2 via immunostaining or flow cytometry on day 9 of differentiation [2].
  • On the final day of differentiation, quantify other characteristic kidney organoid markers like podocalyxin (PODXL), megalin (LRP2), and GATA3 [2].

Mechanism of Action: How DMSO Primes hiPSCs for Differentiation

The molecular mechanism by which DMSO enhances differentiation involves preparing the hiPSCs for lineage commitment.

Signaling Pathway: DMSO-Mediated Priming of hiPSCs

G DMSO DMSO Treatment (1-2%, 24h) PI3K Alters PI3K pathway signaling DMSO->PI3K RB Prevents phosphorylation of Retinoblastoma (RB) protein PI3K->RB CellCycle Cells halt in G1 phase of cell cycle RB->CellCycle Pluripotency Altered expression of pluripotency factors (OCT4, SOX2, etc.) CellCycle->Pluripotency Chromatin Changes in epigenetic landscape CellCycle->Chromatin Outcome Primed hiPSC State Enhanced differentiation potential across all germ layers Pluripotency->Outcome Chromatin->Outcome

As illustrated, DMSO pretreatment is known to prevent the phosphorylation of the retinoblastoma (RB) protein, thereby arresting hiPSCs in the G1 phase of the cell cycle. This arrest is mediated through alterations in PI3K pathway signaling [2]. This cell cycle pause is associated with changes in the expression of genes related to cytoskeletal dynamics, cilium assembly, and cell adhesion, ultimately regulating developmental processes and making the cells more responsive to differentiation cues [2]. This priming effect results in a more efficient transition through intermediate mesoderm and nephron progenitor stages during subsequent kidney organoid differentiation.

Kidney organoids derived from human induced pluripotent stem cells (hiPSCs) represent a transformative tool for modeling renal development, disease, and drug nephrotoxicity [56]. However, these complex three-dimensional structures often exhibit fetal-like characteristics, incomplete nephron segmentation, and limited functional maturity compared to native adult kidney tissue [56] [57]. Current differentiation protocols generate organoids transcriptionally similar to first or second trimester human fetal kidney, lacking integrated vascular systems and exhibiting off-target cell populations [57]. These limitations severely restrict long-term culture and physiological relevance for research and clinical applications.

Dimethyl sulfoxide (DMSO) preconditioning has emerged as a promising biochemical intervention to enhance differentiation efficiency. Recent research demonstrates that treating hiPSCs with low-dose (1-2%) DMSO for 24 hours prior to kidney differentiation significantly enhances the expression of SIX2, a key marker for metanephric mesenchyme nephron progenitor cells [1] [2] [33]. This pretreatment affects the gene expression of pluripotent transcription factors, modifies the epigenetic landscape, and alters hiPSC colony morphology, ultimately improving protocol efficiency toward tubular kidney organoid development [2]. However, DMSO preconditioning represents just one component in a multifaceted approach to organoid maturation that must integrate complementary biochemical and biomechanical strategies to achieve optimal results.

Fundamental Mechanisms of DMSO Action

Molecular and Cellular Effects

DMSO exerts multifaceted effects on stem cell biology that extend beyond its conventional role as a cryoprotectant or solvent. At low concentrations (1-2%), DMSO influences critical signaling pathways that regulate pluripotency and differentiation capacity. Treatment prevents phosphorylation of retinoblastoma protein, arresting cells in the G1 phase of the cell cycle through alterations in PI3K pathway signaling [2]. This cell cycle regulation appears crucial for priming hiPSCs for subsequent differentiation, potentially by synchronizing cells in a state receptive to differentiation cues.

The compound significantly impacts genes involved in cytoskeletal dynamics, cilium assembly, and cell adhesion—all fundamental processes in renal morphogenesis [2]. Furthermore, DMSO modifies the epigenetic landscape of hiPSCs, potentially establishing chromatin configurations more permissive to nephron progenitor specification. These molecular changes manifest structurally as alterations to hiPSC colony morphology, creating a foundation for more efficient differentiation toward renal lineages [2] [33].

Membrane Properties and Oxidative Stress

DMSO's effects on cell membrane fluidity represent another crucial mechanism with implications for differentiation efficiency. Research comparing synovial mesenchymal stem cells (MSCs) and human umbilical vein endothelial cells (HUVECs) revealed that DMSO increases membrane fluidity, particularly in cells with already highly fluidic membranes [58]. This altered fluidity contributes to differential DMSO tolerance among cell types and influences cytoplasmic DMSO influx, subsequently affecting reactive oxygen species (ROS) production and cytotoxicity [58].

Table 1: Cellular Responses to DMSO Exposure

Cell Type Membrane Fluidity Response ROS Sensitivity Differentiation Impact
hiPSCs Moderate increase Moderate Enhanced nephron progenitor differentiation [2]
Synovial MSCs Minimal change Low (high antioxidant capacity) Maintains differentiation potential post-thaw [58]
HUVECs Significant increase High (low antioxidant capacity) Reduced viability, impaired function [58]

The interplay between membrane properties and antioxidant capacity creates cell-type-specific responses to DMSO that researchers must consider when designing differentiation protocols. Strategies that mitigate oxidative stress, such as glutathione supplementation, can improve cell viability in DMSO-sensitive systems [58].

Integrated Experimental Workflow

The following diagram illustrates a comprehensive experimental workflow that integrates DMSO preconditioning with complementary maturation strategies:

G Start hiPSC Culture DMSO DMSO Preconditioning (1-2% for 24h) Start->DMSO Diff Directed Differentiation (Primitive Streak → IM → MM) DMSO->Diff Org 3D Organoid Formation Diff->Org M1 Biomechanical Stimulation (Fluid flow, Substrate stiffness) Org->M1 M2 Biochemical Enhancement (ECM hydrogels, Growth factors) Org->M2 M3 Vascularization Strategies (Co-culture, Angiogenic factors) Org->M3 Assessment Organoid Assessment (Markers, Function, Structure) M1->Assessment M2->Assessment M3->Assessment

Troubleshooting Guide: Common Experimental Challenges

DMSO Preconditioning Issues

Problem: High Cell Death Following DMSO Treatment DMSO cytotoxicity often results from improper concentration or exposure duration, particularly in sensitive cell types.

  • Solution 1: Optimize DMSO concentration using a dose-response curve (0.5-2%) and limit exposure to 24 hours or less [2].
  • Solution 2: Implement a gradual DMSO addition protocol—add DMSO in stepwise increments over several hours to allow osmotic adaptation.
  • Solution 3: Supplement culture media with 1-2mM N-acetylcysteine or other antioxidants to counter DMSO-induced ROS production, especially for sensitive cell types [58].

Problem: Inconsistent Differentiation Outcomes After DMSO Preconditioning Variability may stem from differences in hiPSC colony density, passage number, or pluripotency status.

  • Solution 1: Standardize hiPSC colony morphology and density before DMSO treatment. Target 70-80% confluence with uniform colony edges [2].
  • Solution 2: Use early passage hiPSCs (passage 15-30) and maintain consistent passaging protocols to minimize epigenetic drift.
  • Solution 3: Verify pluripotency marker expression (OCT3/4, SOX2, TRA-1-81, SSEA4) via flow cytometry before DMSO treatment to ensure starting population homogeneity [2].

Integration with Maturation Strategies

Problem: Incomplete Nephron Patterning Despite Combined Approaches Suboptimal temporal application of maturation cues fails to recapitulate developmental sequences.

  • Solution 1: Implement sequential rather than simultaneous application of cues—DMSO preconditioning followed by differentiation induction, then biomechanical stimulation [2] [57].
  • Solution 2: Validate nephron progenitor induction by quantifying SIX2+ cells at day 9 of differentiation before proceeding to maturation phases [1] [2].
  • Solution 3: Use single-cell RNA sequencing to identify off-target cell populations and adjust differentiation conditions accordingly [57].

Problem: Limited Organoid Vascularization Most standard protocols generate predominantly epithelial structures with limited endothelial networks.

  • Solution 1: Incorporate hPSC-derived endothelial organoids during the 3D aggregation phase to promote vascular patterning [57].
  • Solution 2: Supplement cultures with VEGF (50-100 ng/mL) and FGF2 (25-50 ng/mL) after nephron induction to support endothelial cell survival and network formation [56] [57].
  • Solution 3: Utilize microfluidic platforms that create perfusion through organoids, promoting endothelial differentiation and vessel maturation [57].

Biochemical Enhancement Strategies

Extracellular Matrix Optimization

The extracellular matrix (ECM) provides critical biochemical and biophysical cues that guide organoid maturation. Native kidney ECM composition varies significantly across nephron segments and developmental stages, creating specialized microenvironments for distinct cell populations [57]. Traditional organoid culture often relies on generic basement membrane extracts (e.g., Matrigel) that lack kidney-specificity.

Decellularized kidney ECM hydrogels have emerged as promising alternatives that better recapitulate the native renal microenvironment. These scaffolds preserve kidney-specific ECM components and bound signaling factors that promote maturation [57]. Studies demonstrate that kidney-derived ECM hydrogels increase blood vessel network formation and enhance expression of maturation markers in kidney organoids compared to conventional matrices [57].

Table 2: Extracellular Matrix Options for Kidney Organoid Culture

Matrix Type Advantages Limitations Application Timing
Matrigel Standardized, supports organoid formation Tumor-derived, variable lot-to-lot Initial 3D aggregation
Collagen I Defined composition, tunable stiffness Lacks kidney-specific factors Throughout culture
Kidney dECM Kidney-specific composition, enhances maturation Complex preparation, potential immunogenicity After initial nephron induction
Synthetic hydrogels Fully defined, tunable mechanical properties Requires functionalization with adhesive motifs Specialized applications

Growth Factor Patterning

Spatial control of morphogenetic signals represents another powerful strategy to enhance organoid patterning. During kidney development, precise gradients of growth factors like BMP, FGF, and WNT direct tissue patterning and nephron segmentation [59]. Recapitulating this spatial organization in vitro remains challenging but necessary for generating properly patterned organoids.

Biopatterning technologies enable precise deposition of growth factors onto scaffold surfaces, creating defined signaling microenvironments [59]. For example, patterning BMP-2 on stiffer scaffold regions promotes osteogenic differentiation while patterning FGF-2 on more compliant areas supports tenogenic fate, demonstrating how biochemical and biomechanical cues can be integrated to pattern complex tissues [59]. Similar approaches could be adapted for kidney organoids by patterning renal morphogens like GDNF, FGF9, or WNT agonists to guide ureteric bud branching or nephron progenitor differentiation in specific organoid regions.

Biomechanical Stimulation Approaches

Substrate Mechanics and Stiffness Gradients

The mechanical properties of culture substrates profoundly influence cell fate decisions and tissue organization. Native kidney tissue exhibits remarkable mechanical heterogeneity, with stiffness values ranging from ∼1 kPa in the renal cortex to >10 kPa in more structured regions [59]. Traditional organoid culture typically employs compliant substrates that may not adequately recapitulate this mechanical diversity.

Engineered scaffolds with spatially controlled stiffness gradients provide platforms to investigate and exploit mechanobiological cues in kidney organogenesis. Phototunable polyurethane polymers (e.g., QHM polymers) enable creation of scaffolds with tendon-like (0.6 GPa) to bone-like (2.7 GPa) mechanical properties through controlled UV crosslinking [59]. While these values exceed native kidney stiffness, the methodology demonstrates how material properties can be spatially patterned to guide tissue organization. Adapting these approaches to physiologically relevant stiffness ranges (0.2-20 kPa) could promote more appropriate nephron patterning in organoids.

Fluid Flow and Shear Stress

Perfusion systems introduce fluid shear stress, nutrient mixing, and waste removal that enhance organoid viability and maturation. Static culture conditions limit organoid size and complexity due to diffusion constraints, while controlled fluid flow can support larger, more structurally organized tissues [57].

Microfluidic kidney-on-chip platforms create controlled fluid flow conditions that enhance tubular organization, cellular polarity, and vascularization [57]. One study demonstrated that applying fluid shear stress (0.02-0.1 dyn/cm²) in 3D-printed millifluidic chips embedded with gelatin-fibrin ECM enhanced podocyte maturity and improved cellular polarity in kidney organoids [57]. Optimized flow regimens typically involve gradual flow acceleration over several days to avoid detaching developing structures, followed by maintenance at physiological shear stress levels relevant to specific nephron segments.

FAQ: Researcher Questions Answered

Q1: What is the optimal DMSO concentration and treatment duration for hiPSC preconditioning before kidney organoid differentiation?

A: The established optimal protocol uses 1-2% DMSO for 24 hours prior to initiation of differentiation [2]. Treatment should begin on the third day of culture after hiPSCs have been seeded as single cells and allowed to recover for 24 hours. DMSO concentration should be determined empirically for each cell line, as sensitivity can vary. Higher concentrations (>2%) may induce excessive cytotoxicity, while lower concentrations (<0.5%) show minimal preconditioning effects [2] [60].

Q2: How does DMSO preconditioning compare with other small molecule approaches for enhancing differentiation efficiency?

A: DMSO preconditioning operates through distinct mechanisms compared to pathway-specific small molecules. While molecules like CHIR99021 (WNT activation) or RepSox (TGF-β inhibition) target specific signaling pathways, DMSO induces broader changes in cell cycle status, epigenetic landscape, and cytoskeletal organization that prime cells for subsequent differentiation [2]. These approaches can be complementary—DMSO creates a differentiation-receptive state while pathway-specific molecules direct fate specification.

Q3: Can DMSO preconditioning be combined with biomechanical stimulation without adverse effects?

A: Yes, these approaches can be synergistically combined when properly timed. DMSO pretreatment should occur during the 2D culture phase before 3D organoid formation and biomechanical stimulation [2]. Once organoids are established, gradual introduction of biomechanical cues (substrate stiffness, fluid flow) enhances maturation without compromising viability. The sequential application—DMSO preconditioning → differentiation induction → 3D aggregation → biomechanical stimulation—maximizes benefits while minimizing stress.

Q4: What quality control measures should I implement when using DMSO in organoid differentiation?

A: Essential quality control measures include:

  • Verifying DMSO concentration and sterility before use
  • Confirming pluripotency marker expression in hiPSCs before treatment
  • Monitoring cell viability (should remain >80%) during DMSO exposure
  • Quantifying key nephron progenitor markers (SIX2, WT1) at day 7-9 of differentiation
  • Assessing off-target cell types by immunostaining for neural (TUJ1) and muscle (α-SMA) markers
  • Validating enhanced efficiency by comparing SIX2+ cell percentage in DMSO-treated vs. control groups [2]

Q5: How can I assess whether combined maturation strategies are actually improving organoid functionality?

A: Beyond marker expression, functional assessments should include:

  • Albumin uptake assays for proximal tubule function
  • Cilia formation and responsiveness to flow shear stress
  • Electrophysiological measurements of tubular transport
  • Transcriptomic comparison to human fetal kidney reference datasets
  • Demonstration of improved drug toxicity prediction accuracy compared to immature organoids
  • Evidence of segment-specific responses to nephrotoxicants [56] [57]

Research Reagent Solutions

Table 3: Essential Reagents for Combined Maturation Approaches

Reagent Category Specific Examples Function Application Notes
DMSO Formulations Cell culture-grade DMSO (sterile, ≥99.9% purity) Preconditioning hiPSCs for enhanced differentiation Aliquot and store at -20°C; avoid repeated freeze-thaw cycles [2]
ECM Substrates Geltrex (1%), Kidney dECM hydrogels, Collagen I Providing kidney-specific biochemical and biophysical cues Kidney dECM shows superior maturation outcomes compared to standard matrices [57]
Growth Factors FGF9 (10-100 ng/mL), BMP7 (5-50 ng/mL), VEGF (50-100 ng/mL) Directing nephron patterning and vascularization Temporal application critical—FGF9 for nephron progenitor maintenance, VEGF for vascularization [56] [57]
Small Molecules CHIR99021 (3-8 µM), Y-27632 (10 µM) WNT pathway activation, ROCK inhibition for viability CHIR99021 concentration and duration must be optimized for each cell line [57]
Mechanical Culture Systems Microfluidic chips, Spinning bioreactors, Stiffness-tunable hydrogels Applying physiological biomechanical cues Fluid flow rate should be gradually increased to avoid structural damage [57]

Signaling Pathway Integration

The following diagram illustrates key signaling pathways modulated by combined maturation strategies and their functional outcomes in kidney organoids:

G DMSO DMSO Preconditioning PI3K PI3K Pathway Modulation DMSO->PI3K CellCycle G1 Cell Cycle Arrest PI3K->CellCycle Epigenetic Epigenetic Remodeling CellCycle->Epigenetic Outcomes Enhanced Nephron Progenitors Improved Tubular Organization Vascularization Epigenetic->Outcomes Biomechanical Biomechanical Cues (Flow, Stiffness) YAPTAZ YAP/TAZ Activation Biomechanical->YAPTAZ Cytoskeleton Cytoskeletal Reorganization YAPTAZ->Cytoskeleton Cytoskeleton->Outcomes Biochemical Biochemical Cues (GFs, ECM) WNT WNT/β-catenin Signaling Biochemical->WNT FGF FGF Signaling Biochemical->FGF WNT->Outcomes FGF->Outcomes

The integration of DMSO preconditioning with complementary biochemical and biomechanical maturation strategies represents a powerful approach to enhance kidney organoid differentiation efficiency and functional maturity. The synergistic combination of these methods addresses multiple limitations of current organoid technology, including incomplete nephron patterning, fetal-like characteristics, and limited vascularization.

Future advancements will likely focus on further refining the temporal application of these cues to more precisely recapitulate developmental sequences, incorporating patient-specific cells for disease modeling, and establishing standardized quality metrics for organoid functionality. As these integrated approaches mature, they will accelerate the application of kidney organoids in drug screening, disease modeling, and ultimately, regenerative medicine approaches for kidney disease.

Quality Control Checkpoints Throughout the Differentiation Timeline

Generating kidney organoids from human induced pluripotent stem cells (hiPSCs) holds great promise for regenerative medicine, disease modeling, and drug development. However, the efficiency of differentiation protocols remains a significant challenge. This technical support guide outlines critical quality control checkpoints throughout the differentiation timeline, with a specific focus on methodologies enhanced by dimethyl sulfoxide (DMSO) pretreatment. By implementing these checkpoints, researchers can systematically monitor and troubleshoot their experiments to improve the reproducibility and quality of kidney organoid differentiation.

Key Quality Control Checkpoints

Checkpoint 1: Initial hiPSC State Assessment (Day -1 to Day 0)

Purpose: To ensure hiPSCs are in an optimal state before initiating differentiation.

  • Target Cell State: High-quality, undifferentiated hiPSC colonies in a "primed" pluripotent state.
  • Critical Parameters:
    • Colony Morphology: hiPSCs should form flat colonies with defined edges and high nucleus-to-cytoplasm ratio. Monitor for spontaneous differentiation, indicated by loose, non-uniform colonies [2].
    • Pluripotency Markers: Assess expression of key markers via flow cytometry. Target >90% positivity for surface markers (TRA-1-60, TRA-1-81, SSEA-3, SSEA-4) and intracellular transcription factors (OCT3/4, SOX2) [2].
    • DMSO Pretreatment (Optional Enhancement): Treating hiPSCs with 1-2% v/v DMSO for 24 hours in mTeSRPlus medium can precondition cells. DMSO alters colony morphology, affects the epigenetic landscape, and enhances subsequent differentiation efficiency toward nephron progenitors [2] [33] [15].

Troubleshooting FAQ:

  • Q: A significant portion of my hiPSCs are negative for pluripotency markers before differentiation. What should I do?
    • A: Do not proceed with differentiation. Revive a new vial of cells or re-expand the culture. Ensure optimal passaging techniques using gentle dissociation reagent and use of Y-27632 ROCK inhibitor in the medium for 24 hours after passaging to improve cell survival [2].
Checkpoint 2: Primitive Streak and Mesoderm Induction (Days 1-4)

Purpose: To verify successful specification towards mesodermal lineages.

  • Target Cell State: Primitive streak and early intermediate mesoderm (IM) precursors.
  • Critical Parameters:
    • Key Markers: Successful induction is marked by upregulation of TBXT (Brachyury) for primitive streak/mesendodermal precursors, followed by PAX2 and GATA3 for pronephric (anterior) intermediate mesoderm [61].
    • Efficiency: Protocols can achieve nearly 90% efficiency in generating PAX2+/GATA3+ cells [61].
  • Protocol Detail: Cells are typically induced with activators of WNT/β-catenin, FGF, BMP, and TGFβ signaling for 1 day, followed by differentiation using retinoic acid (RA) and FGF with inhibitors of BMP and TGFβ pathways [61].

Troubleshooting FAQ:

  • Q: My cells show low expression of PAX2 and GATA3 at the end of the mesoderm induction phase. How can I improve this?
    • A: First, titrate the concentrations of key signaling molecules (WNT activator, RA). Ensure precise timing of factor addition. If using the ureteric bud protocol, confirm that BMP and TGFβ inhibition is effectively repressing alternative lateral plate mesoderm and endoderm fates [61].
Checkpoint 3: Nephron Progenitor Formation (Days 5-9)

Purpose: To confirm the generation of metanephric mesenchyme (MM) and nephron progenitor cells (NPCs).

  • Target Cell State: MM cells expressing SIX2, a key marker for self-renewing nephron progenitors [2] [1].
  • Critical Parameters:
    • Key Marker: SIX2 is the most critical marker for this stage.
    • DMSO Enhancement: Studies show that hiPSCs pretreated with 1-2% DMSO exhibit enhanced expression of SIX2 after 9 days of kidney organoid differentiation, indicating a more efficient generation of nephron progenitors [2] [33] [15].
  • Protocol Detail: This stage often involves aggregating the IM cells into 3D spheroids using low-attachment plates or microwells. The spheroids then organize over 3-4 days into nephric duct-like tissues or nephron progenitor aggregates [2] [61].

Troubleshooting FAQ:

  • Q: I observe low SIX2 expression at Checkpoint 3. What are potential causes and solutions?
    • A: This can result from suboptimal induction at previous stages. Re-check the quality of your IM cells (Checkpoint 2). Consider incorporating a 24-hour, low-dose (1-2%) DMSO pretreatment step at the hiPSC stage in your workflow to prime the cells for more efficient nephron progenitor differentiation [2].
Checkpoint 4: Organoid Morphogenesis and Patterning (Days 10-18)

Purpose: To assess the 3D organization and regional specification within the forming organoid.

  • Target Cell State: Emergence of patterned nephron structures with distinct proximal and distal domains.
  • Critical Parameters:
    • Morphology: Look for the formation of epithelialized tubules, renal vesicles, comma-shaped, and S-shaped body-like structures, which recapitulate early nephron development [52].
    • Regional Markers:
      • Proximal Precursors: JAG1, HNF1B, and HNF4A. The transition from JAG1+ to HNF4A+ marks advancing proximal tubule precursor maturation [52].
      • Distal/Tubule Markers: GATA3, LRP2 (Megalin) for proximal tubules, PODXL for podocytes [2] [52].
    • Protocol Enhancement for Proximal Bias: To improve proximal tubule differentiation, transient PI3K inhibition can be applied during early nephrogenesis. This activates Notch signaling, shifting differentiation towards proximal precursor states that mature into functional tubules expressing solute carriers [52].

Troubleshooting FAQ:

  • Q: My organoids lack clear patterning and show mixed marker expression in the same regions. How can I fix this?
    • A: This indicates incomplete patterning. Ensure growth factors are fresh and added at the correct concentrations. For generating proximal-biased organoids, consider incorporating a PI3K inhibition step as per relevant protocols [52]. Also, review the composition and batch of the extracellular matrix (e.g., Matrigel) used for 3D embedding, as this can significantly influence morphogenesis [61] [3].
Checkpoint 5: Final Organoid Characterization (Day 19+)

Purpose: To validate the presence and maturity of functional kidney cell types in the mature organoid.

  • Target Cell State: Organoids containing multiple, functionally specialized kidney cell types.
  • Critical Parameters:
    • Cell Type Diversity: Assess for podocytes (PODXL), proximal tubules (LRP2, HNF4A), distal tubules (GATA3), and stromal cells [2] [52].
    • Functional Assessment:
      • Proximal Tubule Function: Evidence of albumin or dextran uptake [52].
      • Injury Response: Exposure to nephrotoxins (e.g., cisplatin) should induce upregulation of injury markers like HAVCR1/KIM1 and SOX9 in proximal tubules, demonstrating physiological relevance [52].
  • Off-Target Cells: Single-cell RNA sequencing has shown that kidney organoids can contain up to 20% non-renal cell populations (e.g., neuronal, muscle). Monitor for these and optimize protocols to minimize their presence [3].

Troubleshooting FAQ:

  • Q: My final organoids have a high percentage of off-target cells. How can I reduce this?
    • A: The presence of off-target cells is a common challenge. To address this, refine the directed differentiation cues at the earliest mesodermal patterning stages. Incorporating synthetic hydrogels with tuned physical and biochemical properties can provide more precise control over cell fate and improve self-organization, reducing off-target populations [3].
Table 1: Quality Control Checkpoints and Markers
Checkpoint Timeline Target Cell State Key Markers to Assess Acceptable Benchmark
hiPSC State Day -1 to 0 Primed Pluripotency OCT3/4, SOX2, TRA-1-60 >90% positivity by flow cytometry [2]
Mesoderm Induction Days 1-4 Anterior Intermediate Mesoderm TBXT, PAX2, GATA3 High efficiency of PAX2+/GATA3+ cells (~90%) [61]
Nephron Progenitor Days 5-9 Metanephric Mesenchyme SIX2 Enhanced expression with DMSO pretreatment [2]
Organoid Patterning Days 10-18 Patterned Nephron Structures JAG1, HNF1B, HNF4A, LRP2 Emergence of distinct proximal (HNF4A+) and distal domains [52]
Final Characterization Day 19+ Mature Kidney Cell Types PODXL, LRP2, GATA3, HAVCR1/KIM1 Presence of multiple nephron segments; functional response to injury [52]
Table 2: Research Reagent Solutions
Reagent Function / Application in Protocol Key Consideration
DMSO (1-2% v/v) Preconditions hiPSCs to enhance differentiation efficiency towards SIX2+ nephron progenitors [2] [15]. Use high-purity, sterile DMSO. Treatment is typically for 24 hours in maintenance medium prior to differentiation initiation.
Geltrex / Matrigel Extracellular matrix coating for 2D hiPSC culture and 3D embedding of organoids to support morphogenesis [2] [61]. Batch variability can significantly impact results. Aliquot and test new lots.
CHIR99021 Small molecule agonist of WNT/β-catenin signaling, used for primitive streak and mesoderm induction [61]. Concentration and exposure time are critical and protocol-dependent. Precise titration is required.
Retinoic Acid (RA) Signaling molecule used to direct differentiation towards intermediate mesoderm fates [61]. Light-sensitive and unstable. Make fresh aliquots and protect from light.
Y-27632 (ROCK inhibitor) Improves survival of dissociated hiPSCs, used during passaging and single-cell seeding [2]. Typically used for 24 hours after passaging or thawing.
PI3K Inhibitor (e.g., LY294002) Applied during nephrogenesis to promote proximal tubule differentiation by activating Notch signaling [52]. Used in specific protocols for generating "proximal-biased" organoids.

Experimental Workflow and Signaling Pathways

Kidney Organoid Differentiation Workflow

G Start hiPSCs (OCT4+, SOX2+) CP1 Checkpoint 1: Pluripotency QC Start->CP1 DMSO DMSO Pretreatment (1-2%, 24h) CP1->DMSO Optional Enhancement PS Primitive Streak Induction (TBXT+) DMSO->PS CP2 Checkpoint 2: Mesoderm QC PS->CP2 IM Intermediate Mesoderm (PAX2+, GATA3+) CP2->IM CP3 Checkpoint 3: Progenitor QC IM->CP3 NPC Nephron Progenitors (SIX2+) CP3->NPC Agg 3D Aggregation NPC->Agg CP4 Checkpoint 4: Patterning QC Agg->CP4 Organoid Kidney Organoid (PODXL+, LRP2+) CP4->Organoid CP5 Checkpoint 5: Maturity QC Organoid->CP5 Mature Mature Organoid (Functional Assays) CP5->Mature

Signaling Pathways in Kidney Organoid Differentiation

Benchmarking the DMSO Method: Functional and Comparative Analysis with Standard Protocols

Frequently Asked Questions

What is the core finding regarding DMSO treatment and kidney organoid differentiation? Treating human induced pluripotent stem cells (hiPSCs) with a low concentration (1-2%) of Dimethyl Sulfoxide (DMSO) for 24 hours before differentiation enhances the expression of the key nephron progenitor marker SIX2 and improves the efficiency of generating kidney organoids [1] [2].

How much can DMSO boost SIX2 expression? Research indicates that DMSO pre-conditioning significantly enhances SIX2 expression after 9 days of kidney organoid differentiation compared to untreated controls [1] [2]. The treatment pushes hiPSCs toward a state more amenable to differentiating into nephron progenitor cells (NPCs), marked by this increase in SIX2 [2].

Why is SIX2 a critical marker in this process? SIX2 is a transcription factor essential for maintaining the self-renewal and stemness of nephron progenitor cells during kidney development [62] [63]. Its presence is a key indicator of a healthy and capable progenitor population that can form functional nephron structures.

My organoids have low SIX2 expression. What could be wrong? Low SIX2 signal can result from several factors:

  • hiPSC Line Variability: Different hiPSC lines may have varying differentiation efficiencies. The protocol has been optimized for specific lines like LUMCi004-C, HUMIMC101, and HUMIMC107 [2].
  • Inconsistent hiPSC Culture: The starting state of your hiPSCs is critical. Maintain colonies with rounded edges and use gentle passaging methods to preserve their "primed" pluripotent state [2].
  • Inaccurate DMSO Concentration: Using DMSO outside the 1-2% range or for an incorrect duration (not 24 hours) can lead to suboptimal or even detrimental effects [2].
  • Poor Seeding Density: Seeding hiPSCs at an incorrect density for your specific cell line can affect differentiation outcomes. Refer to optimized densities (e.g., 1x10^4 cells/cm² for the LUMC line) [2].

The organoids form but appear immature. Can this protocol help? Yes. DMSO treatment influences the epigenetic landscape and gene expression of hiPSCs, priming them for a more efficient differentiation journey. This can lead to the development of more structured tubular kidney organoids [1]. For further maturation, especially of proximal tubules, research suggests that subsequent interventions, such as transient PI3K inhibition to activate Notch signaling, can help generate more mature, proximal-biased organoids [52].

Experimental Protocol: DMSO Pre-Conditioning for Enhanced Kidney Organoids

The following methodology is adapted from Kearney et al. (2025), which investigated the impact of DMSO on hiPSCs for kidney organoid differentiation [2].

1. hiPSC Culture Maintenance

  • Cell Lines Used: LUMCi004-C, HUMIMC101, HUMIMC107 [2].
  • Culture Surface: Coat plates with 1% Geltrex.
  • Medium: Maintain hiPSCs in mTeSRplus medium.
  • Passaging: Use gentle cell dissociation reagent when colony edges are rounded. Gently scrape and break up colonies by pipetting. Reseed at a standard splitting ratio of 1:10.

2. Seeding hiPSCs for Differentiation (Day 0)

  • Dissociate hiPSCs with Accutase for 10 minutes at 37°C to create a single-cell suspension.
  • Resuspend cells in mTeSRplus supplemented with 10 µM Y-27632 (a ROCK inhibitor to enhance survival).
  • Seed cells onto Geltrex-coated plates at line-specific densities:
    • LUMC line: 1.0 x 10^4 cells/cm²
    • HUMIMC101 line: 9.0 x 10^3 cells/cm²
    • HUMIMC107 line: 7.0 x 10^3 cells/cm² [2].

3. DMSO Pre-Treatment (Day 3)

  • On the third day of culture, replace the medium with mTeSRplus supplemented with DMSO.
  • Experimental Groups:
    • Control: mTeSRplus with no DMSO.
    • 1% DMSO: mTeSRplus with 1% (v/v) DMSO.
    • 2% DMSO: mTeSRplus with 2% (v/v) DMSO [2].
  • Incubate the cells with the DMSO medium for 24 hours.

4. Commencing Kidney Organoid Differentiation (Day 4)

  • After 24 hours, remove the DMSO-supplemented medium.
  • Proceed with a standard kidney organoid differentiation protocol, such as the stepwise 2D monolayer-based method developed by Morizane et al. (2017) [1] [2].

5. Quantifying SIX2 Enhancement (Day 9 of Differentiation)

  • Analyze the cells on day 9 of the differentiation protocol, which targets the metanephric mesenchyme nephron progenitor stage.
  • Key Method: Assess SIX2 protein expression using immunostaining or flow cytometry to quantify the boost in nephron progenitor yield [2].

Quantifying the DMSO Effect: Key Experimental Data

Table 1: Summary of Quantitative Findings from DMSO Pre-Treatment Studies

Parameter Findings from DMSO Treatment Experimental Context
Optimal DMSO Concentration 1-2% (v/v) in culture medium [1] [2] Treatment of hiPSCs for 24 hours prior to differentiation.
Key Outcome on Progenitor Marker Enhanced expression of SIX2 protein [1] [2] Analyzed at day 9 of kidney organoid differentiation.
Impact on Pluripotency Altered gene expression of pluripotency factors (OCT3/4, SOX2) and cell surface markers (TRA-1-60, TRA-1-81) [2] Flow cytometry analysis after 24-hour DMSO treatment.
Downstream Morphological Result Improved differentiation efficiency toward tubular kidney organoids [1] Morphological assessment of mature organoids.

The Scientist's Toolkit: Essential Research Reagents

Table 2: Key Reagents for DMSO-Enhanced Kidney Organoid Differentiation

Reagent Function in the Protocol Specification / Note
hiPSCs Starting cell population with potential to differentiate into nephrons. Lines like LUMCi004-C, HUMIMC101, HUMIMC107 [2].
Dimethyl Sulfoxide (DMSO) Pre-conditioning agent that primes hiPSCs for more efficient renal differentiation. Use high-purity, cell culture grade. Final concentration of 1-2% (v/v) [1] [2].
mTeSRplus Medium A defined medium for the maintenance and expansion of hiPSCs. Serves as the base for the DMSO pre-treatment step [2].
Geltrex A solubilized basement membrane extract used to coat culture surfaces. Provides a substrate for hiPSC attachment and growth. Typically used at 1% [2].
Y-27632 (ROCK inhibitor) Improves the survival of hiPSCs after single-cell passaging. Supplement in the seeding medium at 10 µM [2].
Accutase A cell detachment solution used to generate a single-cell suspension. Preferable for accurate cell counting and seeding [2].
SIX2 Antibody Critical tool for quantifying the output of nephron progenitor cells. Used for immunostaining or flow cytometry to validate protocol success [2].

Visualizing the Workflow and Mechanism

The diagram below illustrates the experimental workflow and a proposed mechanism for how DMSO preconditioning enhances nephron progenitor yield, linked to the METTL3-mediated RNA transmethylation pathway, a known regulator of NPC differentiation [64].

G cluster_workflow Experimental Workflow hiPSCs hiPSCs DMSO DMSO hiPSCs->DMSO Preconditioned_iPSCs Preconditioned hiPSCs (Altered epigenetics & morphology) DMSO->Preconditioned_iPSCs METTL3_Pathway Enhanced METTL3 Activity? (m6A RNA methylation) DMSO->METTL3_Pathway Kidney_Organoid_Protocol Kidney Organoid Protocol (e.g., Morizane et al.) Preconditioned_iPSCs->Kidney_Organoid_Protocol High_SIX2_NPCs High-SIX2 Nephron Progenitor Cells (NPCs) Kidney_Organoid_Protocol->High_SIX2_NPCs Improved_Organoids Improved Tubular Kidney Organoids High_SIX2_NPCs->Improved_Organoids METTL3_Pathway->High_SIX2_NPCs

Diagram 1: DMSO preconditioning workflow for enhanced NPC yield.

The relationship between DMSO preconditioning and the METTL3-SAM pathway is a proposed mechanistic hypothesis based on parallel research. The METTL3-SAM axis is a crucial metabolic and epitranscriptomic regulator of NPC differentiation [64]. Future studies should directly investigate if DMSO's effects are mediated through this pathway.

G Methionine Methionine SAM S-Adenosylmethionine (SAM) Methionine->SAM METTL3 METTL3-METTL14 Writer Complex SAM->METTL3  Binds & Activates m6A_mRNA m6A mRNA Modification METTL3->m6A_mRNA  Catalyzes NPC_Differentiation NPC Differentiation & SIX2 Regulation m6A_mRNA->NPC_Differentiation Promotes DMSO_Input DMSO Preconditioning DMSO_Input->METTL3  Potential Upregulation

Diagram 2: METTL3-SAM pathway in NPC differentiation.

Should you have any further questions or require additional troubleshooting, please contact your institutional core facility or the corresponding authors of the cited literature.

Superior Tubular Morphology in DMSO-Conditioned Organoids

Frequently Asked Questions (FAQs)

Implementation & Protocol

Q1: What is the specific DMSO conditioning protocol for enhancing kidney organoid differentiation? The protocol involves treating human induced pluripotent stem cells (hiPSCs) with a low concentration of DMSO prior to and during the initiation of kidney differentiation [1].

  • DMSO Concentration: Use a final concentration of 1-2% (vol/vol) DMSO [1].
  • Treatment Timing: Apply DMSO at the hiPSC pluripotency stage and during the early phases of differentiation, as it influences the cells' epigenetic landscape and gene expression, priming them for a more efficient differentiation trajectory [1].
  • Differentiation Method: This conditioning enhances the efficiency of the widely used Morizane 2D monolayer-based kidney organoid differentiation protocol [1].

Q2: How do I assess if the DMSO treatment is working? Key success indicators are measured at specific time points during differentiation.

  • Day 9: Analyze for enhanced expression of SIX2, a key marker for metanephric mesenchyme nephron progenitors. A significant increase is a primary indicator of successful conditioning [1].
  • Endpoint (Day ~26-30): Evaluate the overall organoid structure. Successful differentiation will result in organoids with a higher proportion of well-formed, segmented tubular structures and a more robust morphology [1].
Troubleshooting

Q3: My organoids show high variability after DMSO treatment. What could be the cause? Organoid variability is a common challenge. DMSO conditioning is one strategy to improve efficiency, but other sources of variability must be controlled [65].

  • Initial Cell Composition: Precise control over the initial number and ratio of progenitor cells is critical for reproducible organoid formation. Techniques like DNA-programmed assembly of cells (DPAC) can standardize this [65].
  • Culture Platform: Consider using advanced microfluidic platforms (e.g., OrganoidChip+) that provide a uniform environment, better reagent delivery, and immobilization for consistent growth and analysis [66].
  • DMSO Quality: Use high-purity, cell culture-tested DMSO to avoid batch-specific contaminants.

Q4: I'm not observing the expected boost in SIX2+ progenitors. What should I check?

  • Verify hiPSC Pluripotency: Ensure your starting hiPSC population is healthy, has a normal karyotype, and is in a primed state of pluripotency before initiating DMSO treatment [1].
  • Confirm DMSO Concentration: Re-check the dilution of your DMSO stock. Concentrations significantly above 2% may be cytotoxic, while lower concentrations may be ineffective [1] [67].
  • Check Reagent Quality: The activity of growth factors (e.g., Wnts, FGFs) in your differentiation medium is crucial. Use fresh, high-quality reagents.

Q5: How can I best image and quantify the improved tubular morphology? For high-quality imaging and quantification, standardize your imaging pipeline.

  • Platform: Use platforms designed for high-content imaging, like the OrganoidChip+, which immobilizes organoids and provides a thin substrate for high-resolution microscopy without the need for transfer [66].
  • Imaging & Analysis:
    • Staining: Perform immunofluorescence staining for tubular markers (e.g., LTL for proximal tubules, E-Cadherin for epithelial structures).
    • Imaging: Acquire z-stack images using confocal microscopy.
    • Quantification: Use image analysis software (e.g., ImageJ, CellProfiler) to quantify parameters like tubular diameter, lumen formation, and the percentage of the organoid area positive for tubular markers.
Validation & Scaling

Q6: What functional evidence supports the "superiority" of tubular morphology in these organoids? While structural maturity is a key indicator, functional validation is the gold standard. You can assess:

  • Transcriptomic Profiling: Conduct RNA sequencing to confirm that DMSO-conditioned organoids have an expression profile enriched for mature tubular cell genes and kidney development pathways [68].
  • Transport Function: Perform dye uptake assays (e.g., Albumin-FITC) to test for receptor-mediated endocytosis in proximal tubules.
  • Drug Toxicity Testing: Use the organoids for drug screening. Improved tubular morphology may lead to more accurate predictions of drug-induced nephrotoxicity, as differentiated cell types can show different susceptibility [68] [69].

Q7: Can this DMSO conditioning approach be scaled for high-throughput drug screening? Yes, the approach is scalable.

  • Culture Format: The DMSO treatment is a media-based intervention compatible with multi-well plates.
  • Automation: Couple the protocol with automated liquid handling systems for seeding, feeding, and DMSO dosing.
  • Miniaturization: Use 96- or 384-well formats with micropatterning or hydrogel droplets to generate thousands of uniform micro-organoids [65]. The OrganoidChip+ is also designed for parallel culturing and imaging of multiple organoids [66].

Experimental Protocols & Data

Detailed DMSO Conditioning Protocol

Title: Enhanced Differentiation of hiPSCs to Kidney Organoids Using DMSO Conditioning Application: This protocol is designed to improve the efficiency of generating nephron progenitor cells and subsequent kidney organoids with superior tubular morphology from hiPSCs [1].

Reagents:

  • hiPSCs cultured in primed pluripotency medium
  • Essential 8 or mTeSR1 medium
  • Dimethyl Sulfoxide (DMSO), cell culture grade
  • Kidney organoid differentiation media (as per Morizane et al. 2017 protocol)
  • Phosphate Buffered Saline (PBS)
  • Accutase or EDTA

Procedure:

  • Culture hiPSCs: Maintain hiPSCs in a primed state of pluripotency. Culture until they are ~80% confluent with typical compact colony morphology.
  • Prepare DMSO Medium: Supplement standard hiPSC culture medium with DMSO to a final concentration of 1-2% (vol/vol). For example, add 10-20 µL of DMSO to 1 mL of medium.
  • DMSO Conditioning: Replace the existing hiPSC culture medium with the DMSO-supplemented medium. Incubate the cells for 24-48 hours.
  • Initiate Differentiation: Following the conditioning period, dissociate the hiPSCs into a single-cell suspension. Begin the kidney organoid differentiation protocol (e.g., Morizane 2017), maintaining the 1-2% DMSO in the media for the first few days of differentiation.
  • Continue Differentiation: After the initial phase, continue with the standard kidney organoid differentiation protocol without DMSO for the remaining duration (typically 21-25 days total).

Notes:

  • Always include a control group of hiPSCs differentiated without DMSO conditioning for comparison.
  • Monitor hiPSC colony morphology during DMSO treatment; changes indicate the treatment is affecting the cells [1].

Table 1: Key Quantitative Outcomes of DMSO-Conditioned Kidney Organoid Differentiation

Parameter Control Organoids (No DMSO) DMSO-Conditioned Organoids Measurement Method Citation
SIX2+ Nephron Progenitors (Day 9) Baseline Significantly Enhanced qPCR / Immunofluorescence [1]
Tubular Structure Formation Less robust, variable More robust and efficient Brightfield & IF Microscopy [1]
Differentiation Protocol Efficiency Standard efficiency Improved Morphological scoring [1]
DMSO Concentration 0% 1-2% N/A [1]

Table 2: Essential Research Reagent Solutions for DMSO-Conditioned Kidney Organoid Experiments

Reagent / Material Function / Role in the Protocol Key Details / Considerations
Human iPSCs The starting cell population for generating kidney organoids. Must be in a "primed" state of pluripotency. Quality controls for karyotype and pluripotency markers are essential [1].
Cell Culture-Grade DMSO Conditions hiPSCs to enhance kidney differentiation potential. Use high-purity, sterile-filtered DMSO. Final working concentration of 1-2% [1] [67].
Recombinant Growth Factors Directs stepwise differentiation towards kidney lineages (e.g., CHIR99021, FGF9, BMP7). Follow established kidney organoid protocols (e.g., Morizane 2017). Activity between lots should be verified.
Extracellular Matrix (e.g., Matrigel) Provides a 3D scaffold that supports organoid growth and self-organization. Growth factor-reduced matrices are often preferred. Keep on ice to prevent premature polymerization [70].
SIX2 Antibody Validates the successful generation of nephron progenitor cells, a key outcome of DMSO conditioning. A primary marker for quality control at the progenitor stage (Day 9) [1].
Tubular Markers (e.g., LTL, E-Cadherin) Assesses the final outcome of superior tubular morphology in mature organoids. Use for immunofluorescence to quantify tubular structures and lumen formation [65].

Signaling Pathways and Workflows

G Start hiPSCs in Primed State DMSO_Treatment DMSO Conditioning (1-2% for 24-48h) Start->DMSO_Treatment Epigenetic_Change Alters Epigenetic Landscape DMSO_Treatment->Epigenetic_Change Gene_Expression Changes Gene Expression of Pluripotency Factors DMSO_Treatment->Gene_Expression Initiate_Diff Initiate Kidney Differentiation (Morizane Protocol) Epigenetic_Change->Initiate_Diff Gene_Expression->Initiate_Diff Progenitor_Stage Enhanced SIX2+ Nephron Progenitor Population Initiate_Diff->Progenitor_Stage Organoid_Formation Kidney Organoid Maturation Progenitor_Stage->Organoid_Formation Superior_Tubules Superior Tubular Morphology & Robust Organoids Organoid_Formation->Superior_Tubules

DMSO Conditioning Workflow for Kidney Organoids

G DMSO DMSO Treatment Wnt Wnt/ β-catenin DMSO->Wnt Potentiates Epigenetic Epigenetic Remodeling DMSO->Epigenetic Induces Progenitors Expanded Nephron Progenitors (SIX2+) Wnt->Progenitors Enhances Epigenetic->Progenitors Primes Tubules Superior Tubular Morphology Progenitors->Tubules Differentiate to

Signaling Pathway Hypothesis

Comparative Analysis with Other Optimization Strategies (e.g., PI3K Inhibition)

The pursuit of robust and physiologically accurate kidney organoids has led to the development of various differentiation optimization strategies. Two prominent approaches involve the use of the common laboratory solvent Dimethyl Sulfoxide (DMSO) and the targeted inhibition of the PI3K signaling pathway. While both aim to enhance differentiation efficiency, they operate through distinct molecular mechanisms and produce different phenotypic outcomes in the resulting organoids. This guide provides a comparative technical analysis to help researchers select and troubleshoot the most appropriate method for their experimental goals.

FAQ: Strategy Selection and Conceptual Understanding

Q1: What is the fundamental difference between using DMSO and PI3K inhibition for kidney organoid differentiation?

The core difference lies in their primary target and effect. DMSO acts as a broad conditioning agent that prepares pluripotent stem cells for differentiation, whereas PI3K inhibition is a precise intervention applied during early nephrogenesis to steer cell fate towards proximal tubule lineages [2] [52].

Q2: When should I choose DMSO treatment over PI3K inhibition?

Choose DMSO treatment if your goal is to generally enhance the efficiency of nephron progenitor formation and improve the overall robustness of tubular structures in your organoids [2] [15]. Choose PI3K inhibition if your research specifically requires a high yield of proximal tubule cells, for instance, for modeling tubular injury or drug transport studies [52].

Q3: Can DMSO and PI3K inhibition be combined in a protocol?

Current literature does not report on the combination of these two specific strategies. Their mechanisms act on different stages and processes—DMSO on the initial pluripotent state and PI3K inhibition on early nephrogenesis. Combining them could lead to unpredictable results and is not recommended without extensive empirical testing.

Troubleshooting Guide: Common Experimental Issues

Problem Phenotype Possible Cause in DMSO Protocol Possible Cause in PI3K Inhibition Protocol Suggested Remedial Action
Low Efficiency of Target Cell Type DMSO concentration suboptimal [2] Timing of inhibitor addition incorrect [52] Titrate DMSO (0.5-2%); Verify differentiation window (PTA-to-RV transition for PI3Ki).
High Organoid Variability Inconsistent hiPSC colony morphology post-treatment [2] Uncontrolled spontaneous patterning dominating [71] Standardize hiPSC seeding density and colony size before DMSO treatment.
Poor Proximal Tubule Maturation Protocol inherently biased towards progenitors [2] Incomplete Notch activation or short culture [52] Extend culture; Confirm HNF4A expression.
Off-Target Cell Types Prolonged DMSO exposure Unoptimized WNT/BMP signaling balance [71] Limit DMSO to 24h; Screen WNT/BMP modulator concentrations.
Cell Death During Treatment DMSO cytotoxicity [2] PI3K inhibitor toxicity [52] Reduce DMSO concentration (start at 0.5%); Titrate inhibitor dose.

Comparative Data: DMSO vs. PI3K Inhibition

Table 1: Direct comparison of key experimental parameters and outcomes between DMSO treatment and PI3K inhibition.

Parameter DMSO Treatment PI3K Inhibition
Primary Objective Enhance nephron progenitor yield & general differentiation efficiency [2] Generate proximal-biased nephrons with emerging maturity [52]
Key Molecular Mechanism Alters hiPSC colony morphology, gene expression, and epigenetic landscape [2] Activates Notch signaling, shifting axial differentiation toward proximal states [52]
Typical Concentration/Dose 1-2% (v/v) [2] Not specified in available literature (requires original ref. consultation)
Treatment Duration 24 hours [2] Transient (during early nephrogenesis) [52]
Critical Markers Post-Treatment ↑ SIX2 (Nephron Progenitor) [2] ↑ HNF4A, ↑ HNF1B, ↑ Solute Carriers (SLCs) [52]
Major Outcome More robust and efficient kidney organoid formation [2] [15] Proximal convoluted tubule cells with physiological function (transport) [52]
Best Application Disease modeling, drug screens requiring broad nephron segments [2] Nephrotoxicity testing, proximal tubulopathy disease modeling [52]

Experimental Protocols

Protocol 1: DMSO Pre-Conditioning for Enhanced Nephron Progenitors

This protocol is adapted from Kearney et al. (2025) and should be initiated with hiPSCs at a high confluence and optimal colony morphology [2].

  • Culture and Seeding: Maintain hiPSCs on a suitable extracellular matrix (e.g., Geltrex). To begin differentiation, create a single-cell suspension using Accutase and seed the cells at a density optimized for your cell line (e.g., 7,000 - 10,000 cells/cm²) in mTeSRPlus medium supplemented with a Rho kinase (ROCK) inhibitor [2].
  • DMSO Treatment (24 hours): 24 hours after seeding, replace the medium with fresh mTeSRPlus supplemented with 1-2% (v/v) DMSO. Incubate for 24 hours [2].
  • Kidney Differentiation: Following DMSO exposure, remove the DMSO-containing medium completely. Commence your standard kidney organoid differentiation protocol (e.g., the stepwise 2D monolayer-based protocol by Morizane et al.) from the beginning [2].
  • Validation: On day 9 of differentiation, assess the efficiency of nephron progenitor induction by quantifying cells positive for SIX2 protein [2].
Protocol 2: PI3K Inhibition for Proximal-Biased Organoids

This protocol summary is based on the work described in Nature Communications (2025), which involves transient PI3K inhibition during a critical window of early nephrogenesis [52].

  • Generate Kidney Organoids: Differentiate hiPSCs into kidney organoids using your base protocol until the formation of pretubular aggregates (PTAs) and early renal vesicles (RVs). This typically occurs around differentiation day 10-12 in many protocols [52] [71].
  • PI3K Inhibitor Application: During this early nephrogenesis window, supplement the organoid culture medium with a PI3K inhibitor. The specific inhibitor and concentration should be determined from the original reference [52].
  • Transient Treatment: The application is transient. Remove the inhibitor-containing medium after the specified treatment period (e.g., 24-48 hours) and continue culture in standard organoid differentiation medium [52].
  • Validation: Analyze the resulting organoids for a proximal-biased phenotype. Key validation markers include:
    • Immunofluorescence: High nuclear expression of HNF4A and HNF1B.
    • Functional Assessment: Expression of solute carriers (e.g., for organic cations/anions) and demonstrated transport function (e.g., albumin/dextran uptake) [52].

G DMSO DMSO Altered_Morphology Altered Colony Morphology & Epigenetic Landscape DMSO->Altered_Morphology Pluripotent_State Primed Pluripotent State Pluripotent_State->DMSO Enhanced_Progenitors Enhanced SIX2+ Nephron Progenitors Altered_Morphology->Enhanced_Progenitors Robust_Organoids Robust Tubular Organoids Enhanced_Progenitors->Robust_Organoids PI3Ki PI3Ki Notch_Activation Notch Signaling Activation PI3Ki->Notch_Activation Early_Nephrogenesis Early Nephrogenesis (PTA/RV Stage) Early_Nephrogenesis->PI3Ki Proximal_Bias Proximal Tubule Bias (HNF4A+/HNF1B+) Notch_Activation->Proximal_Bias Mature_Function Emerging Maturity (Solute Carriers, Transport) Proximal_Bias->Mature_Function

Diagram 1: Signaling pathways and outcomes for DMSO and PI3K inhibition strategies.

Research Reagent Solutions

Table 2: Essential materials and reagents for implementing the described optimization strategies.

Item Function in Protocol Example/Catalog Consideration
Dimethyl Sulfoxide (DMSO) Pre-conditions hiPSCs, enhancing differentiation potential into nephron progenitors [2]. Cell culture grade, sterile-filtered.
PI3K Inhibitor Applied transiently during early nephrogenesis to promote proximal tubule fate via Notch activation [52]. Specific inhibitor (e.g., LY294002).
hiPSCs Starting cell source for kidney organoid differentiation. Use well-characterized lines (e.g., LUMC0031iCTRL08, HUMIMC101) [2].
SIX2 Antibody Key marker for validating increased nephron progenitor population in DMSO-treated cultures [2]. Validated for immunofluorescence/flow cytometry.
HNF4A Antibody Critical transcription factor marker for identifying mature proximal tubule cells in PI3Ki-treated organoids [52]. Validated for immunofluorescence.
HNF1B Antibody Marks proximal and medial nephron precursors; used to validate proximal bias [52] [71]. Validated for immunofluorescence.
Geltrex / Matrigel Extracellular matrix for culturing hiPSCs and supporting 3D organoid formation. Suitable for pluripotent stem cell culture.
mTeSRPlus Medium Feeder-free, defined medium for the maintenance and expansion of hiPSCs. Commercially available.

G Start Start Experiment Goal Define Primary Goal Start->Goal Goal_Progenitors Maximize Nephron Progenitors Goal->Goal_Progenitors Goal_Proximal Generate Proximal Tubule Cells Goal->Goal_Proximal Subgraph_Cluster Method_DMSO Apply DMSO Pre-Conditioning Goal_Progenitors->Method_DMSO Method_PI3Ki Apply Transient PI3K Inhibition Goal_Proximal->Method_PI3Ki Validate_Progenitors Validate: SIX2+ Cells Method_DMSO->Validate_Progenitors Validate_Proximal Validate: HNF4A+ Cells & Transport Function Method_PI3Ki->Validate_Proximal

Diagram 2: Decision workflow for selecting an optimization strategy.

Frequently Asked Questions (FAQs)

FAQ 1: How does DMSO treatment specifically enhance kidney organoid differentiation? Low-dose (1-2%) Dimethyl Sulfoxide (DMSO) pre-treatment of human induced pluripotent stem cells (hiPSCs) modifies the cells' gene expression, epigenetic landscape, and colony morphology. These changes prime the hiPSCs, making them more amenable to differentiation and leading to a significant increase in the expression of SIX2, a key transcription factor and marker for metanephric mesenchyme nephron progenitors, after 9 days of kidney organoid differentiation. This results in more efficient generation of tubular kidney organoids [1] [33].

FAQ 2: What are the primary advantages of using kidney organoids for nephrotoxicity screening? Kidney organoids derived from hiPSCs offer a human-relevant, in vitro model that can recapitulate complex kidney structures containing multiple cell types. They are particularly valuable for:

  • Early-stage drug discovery: They help identify renal toxic compounds earlier in the drug development pipeline, reducing late-stage failures [72].
  • Biomarker investigation: They allow for the study of sensitive and renal-specific injury biomarkers like KIM-1 and NGAL in a human model [72].
  • Mechanistic studies: They enable researchers to elucidate the pathways and mechanisms of Drug-Induced Nephrotoxicity (DIN) in a controlled environment [73].

FAQ 3: What are the current limitations in DIN prediction that advanced models aim to solve? Traditional methods for predicting DIN face several challenges:

  • Functional Reserve: Kidneys can compensate for damage, delaying the detection of injury until significant harm has occurred [73].
  • Insensitive Biomarkers: Reliance on serum creatinine (SCr) and blood urea nitrogen (BUN) is problematic because their levels change only after a substantial (24-48 hour) delay post-injury, and they can be influenced by non-renal factors like muscle mass [73].
  • Species Differences: Preclinical animal models often do not fully translate to human toxicity outcomes [74] [75].

FAQ 4: How can AI and machine learning be integrated into nephrotoxicity assessment? AI models can predict DIN risk by analyzing chemical structures, thereby providing an in silico tool for early compound screening. A robust workflow includes:

  • Data Curation: Building high-quality datasets from sources like SIDER, FDA, ChEMBL, and DrugBank [74].
  • Model Training: Using molecular fingerprints (e.g., ECFP_6) with Deep Neural Networks (DNNs), which have been shown to outperform traditional machine learning algorithms [74].
  • Interpretation: Applying methods like SHapley Additive exPlanations (SHAP) to identify structural fragments associated with nephrotoxicity, providing early warning alerts for chemists [74].

Troubleshooting Guides

Table 1: Common Kidney Organoid Differentiation Issues

Problem Potential Cause Solution
Low expression of nephron progenitor markers (e.g., SIX2) Suboptimal hiPSC priming state; Inefficient differentiation protocol Pre-treat hiPSCs with 1-2% DMSO for 48 hours prior to initiating differentiation to enhance epigenetic priming [1] [33].
High variability in organoid formation Inconsistent hiPSC colony morphology or health Standardize hiPSC culture conditions and use cells at a consistent passage number. DMSO treatment can help synchronize colony morphology [1].
Poor reproducibility of nephrotoxicity results Use of insensitive or non-specific endpoints Implement a multiplexed assay panel that includes novel biomarkers like KIM-1 and NGAL, in addition to traditional viability assays [72].

Table 2: Challenges in Drug-Induced Nephrotoxicity (DIN) Prediction

Challenge Mitigation Strategy
Delayed detection with standard biomarkers (SCr, BUN) Incorporate novel, sensitive biomarkers (KIM-1, NGAL) for early detection of tubular injury [73] [72].
Difficulty predicting risk from chemical structure alone Integrate in silico AI-based prediction models using molecular fingerprints (e.g., ECFP_6) to flag high-risk compounds early [74].
Distinguishing adaptive responses from true toxicity Utilize functional assays, such as Mitochondrial Stress Assessment, to detect sub-lethal cellular stress [72].

Summarized Quantitative Data

Table 3: AI Model Performance in Predicting Nephrotoxicity

This table summarizes the performance of a Deep Neural Network (DNN) model using different molecular fingerprints for predicting drug-induced nephrotoxicity. The ECFP_6 fingerprint demonstrated superior performance [74].

Molecular Fingerprint AUC Accuracy (ACC) F1-Score
ECFP_6 75.9% 71.4% 76.0%
Other Fingerprint 1 72.1% 68.5% 71.8%
Other Fingerprint 2 70.5% 66.2% 69.3%

Table 4: Biomarkers for Detecting Drug-Induced Nephrotoxicity

A comparison of key biomarkers used for detecting kidney injury, highlighting the advantages of novel biomarkers over traditional ones [73] [72].

Biomarker Type Key Characteristics & Utility
KIM-1 Novel / Renal Specific Sensitive and specific biomarker for early proximal tubule injury.
NGAL Novel / Rapid Response Correlates with renal toxicity; rapidly over-expressed upon insult.
Serum Creatinine (SCr) Traditional / Functional Common clinical measure, but changes are delayed (24-48 hrs) and non-specific.
Blood Urea Nitrogen (BUN) Traditional / Functional Can be elevated in kidney injury, but also influenced by diet and hydration.

Experimental Protocols

Protocol 1: DMSO-Enhanced Kidney Organoid Differentiation

This protocol is adapted from Kearney et al. (2025) for enhancing the differentiation of hiPSCs into kidney organoids [1] [33].

Key Reagents:

  • Human induced pluripotent stem cells (hiPSCs)
  • Dimethyl Sulfoxide (DMSO), cell culture grade
  • Standard hiPSC culture medium
  • Kidney organoid differentiation media (as per Morizane et al. 2017 protocol)

Methodology:

  • hiPSC Culture: Maintain hiPSCs under standard conditions in a primed state of pluripotency.
  • DMSO Pre-treatment: At the start of differentiation, treat hiPSCs with low-dose DMSO (1-2% v/v) in culture medium for 48 hours.
  • Differentiation: Following pre-treatment, initiate the stepwise, 2D monolayer-based kidney organoid differentiation protocol.
  • Monitoring: After 9 days of differentiation, analyze the cells for enhanced expression of the nephron progenitor marker SIX2 using qPCR or immunostaining to confirm improved efficiency.

Protocol 2: Multiplexed In Vitro Nephrotoxicity Assay

This protocol outlines a cell-based approach for screening compound-induced nephrotoxicity, utilizing human renal cells [72].

Key Reagents:

  • Human Renal Proximal Tubule Epithelial Cells (HRPTEpiC) or Human Renal Epithelial Cells (HREpC)
  • Test compounds at various doses
  • Assay kits for cytotoxicity, caspase-3, mitochondrial membrane potential, KIM-1, and NGAL

Methodology:

  • Cell Seeding: Culture HRPTEpiC or HREpC in appropriate plates.
  • Compound Treatment: Incubate cells with the test compounds across a range of doses for 24-72 hours.
  • Endpoint Analysis: Perform a multiplexed assessment using high-content analysis:
    • Cytotoxicity: Measure cell viability (e.g., IC50 calculation).
    • Apoptosis: Quantify caspase-3 activation.
    • Mitochondrial Stress: Assess mitochondrial membrane potential and cytochrome C release.
    • Biomarker Detection: Quantify expression levels of KIM-1 and NGAL in cell lysates or supernatant.
  • Data Integration: Combine results from all endpoints to provide a comprehensive nephrotoxicity profile for each compound.

Signaling Pathways and Workflows

DMSO_Workflow Start hiPSCs in Primed State DMSO DMSO Treatment (1-2%) Start->DMSO Changes Induced Changes DMSO->Changes Sub1 Altered Gene Expression Changes->Sub1 Sub2 Epigenetic Reconfiguration Changes->Sub2 Sub3 Altered Colony Morphology Changes->Sub3 Outcome Enhanced Differentiation Efficiency Sub1->Outcome Sub2->Outcome Sub3->Outcome Marker Increased SIX2+ Nephron Progenitors Outcome->Marker

Diagram Title: DMSO Enhancement of Kidney Organoid Differentiation

AI_Prediction Data Data Curation (1,018 Compounds) FP Molecular Fingerprint Generation (e.g., ECFP_6) Data->FP Model DNN Model Training FP->Model Prediction Nephrotoxicity Prediction Model->Prediction Interpret Model Interpretation (SHAP Analysis) Prediction->Interpret Output Identification of Structural Alerts Interpret->Output

Diagram Title: AI-Driven Nephrotoxicity Prediction Workflow

The Scientist's Toolkit: Research Reagent Solutions

Table 5: Essential Materials for Nephrotoxicity and Organoid Research

Item Function / Application
Human induced Pluripotent Stem Cells (hiPSCs) The starting cell source for generating patient-specific kidney organoids [1] [33].
Dimethyl Sulfoxide (DMSO) Used as a priming agent to enhance the differentiation efficiency of hiPSCs into nephron progenitors [1] [33].
Human Renal Proximal Tubule Epithelial Cells (HRPTEpiC) Primary cells used for in vitro nephrotoxicity assays, as the proximal tubule is a primary site of drug-induced injury [72].
KIM-1 & NGAL Assay Kits Used for the sensitive and early detection of drug-induced tubular injury in cell cultures or supernatants [72].
Caspase-3 Assay Kits Reagents to detect apoptosis activation, a common mechanism of nephrotoxicity [72].
Mitochondrial Stress Dyes Probes to assess mitochondrial membrane potential, an early indicator of cellular stress and health [72].
Molecular Fingerprinting Software Computational tools to generate molecular representations (e.g., ECFP_6) for in silico toxicity prediction [74].

Limitations and How the DMSO Method Addresses Current Organoid Shortcomings

For researchers in regenerative medicine and drug development, kidney organoids derived from human induced pluripotent stem cells (hiPSCs) represent a transformative tool for modeling diseases, conducting nephrotoxicity screening, and developing future renal replacement therapies [1] [3]. However, the field grapples with persistent challenges including limited differentiation efficiency, immature cellular phenotypes, and the presence of off-target cell populations [3]. This technical support article explores how pretreatment with dimethyl sulfoxide (DMSO), a common laboratory solvent, can address these limitations and provides a practical guide for its implementation.

Frequently Asked Questions (FAQs)

Q1: What are the primary limitations of current kidney organoid differentiation protocols? Current protocols face several key challenges:

  • Inefficient Differentiation: Generating complex structures with multiple cell types remains challenging, often resulting in heterogeneous organoids [1] [2].
  • Off-Target Cell Populations: Single-cell transcriptomics has identified that up to 20% of cells in kidney organoids can be non-renal, including neuronal, muscle, and melanoma cell populations [3].
  • Immature Phenotypes: Kidney organoids most closely resemble first-trimester fetal kidneys and struggle to achieve adult-like maturity and functionality [3].
  • Protocol Variability: The reliance on self-organization without sufficient control mechanisms leads to inconsistencies between batches [3].

Q2: How does DMSO pretreatment improve kidney organoid differentiation? Recent research demonstrates that treating hiPSCs with low-dose DMSO (1-2%) for 24 hours prior to differentiation:

  • Enhances Nephron Progenitor Formation: Significantly boosts expression of SIX2, a key marker for metanephric mesenchyme nephron progenitor cells [1] [2].
  • Modifies Pluripotency State: Alters the gene expression of pluripotent transcription factors and the epigenetic landscape, priming cells for more efficient differentiation [1] [2].
  • Improves Tubular Structure Development: Promotes the development of better-formed tubular kidney organoids [1].

Q3: What is the proposed mechanism behind DMSO's effect on differentiation efficiency? While research is ongoing, current evidence suggests:

  • Cell Cycle Regulation: DMSO prevents phosphorylation of retinoblastoma protein, halting cells in the G1 phase via alterations in PI3K pathway signalling [2].
  • Reduced Growth Factor Threshold: In other endodermal lineages, DMSO has been shown to lower the concentration of Activin required for definitive endoderm differentiation from 100 ng/ml to 6.25 ng/ml [76].
  • Gene Expression Changes: DMSO influences genes involved in cytoskeletal dynamics, cilium assembly, and cell adhesion—processes critical for proper organogenesis [2].

Q4: What are the key technical considerations when implementing DMSO treatment?

  • Optimal Concentration: Use 1-2% DMSO concentration in culture medium [1] [2].
  • Treatment Duration: Apply DMSO for 24 hours prior to initiating differentiation protocols [2].
  • Timing: Administer treatment on the third day of culture, after cell seeding and attachment [2].
  • Cell Line Variability: Note that different hiPSC lines may require optimization of seeding densities and potentially slight adjustments to DMSO exposure [2].

Troubleshooting Guides

Problem: Low Expression of Nephron Progenitor Markers

Potential Causes and Solutions:

  • Cause: Inconsistent DMSO concentration
    • Solution: Prepare fresh DMSO solutions and verify concentration calculations. Use high-purity, medical-grade DMSO to ensure consistency [77].
  • Cause: Suboptimal treatment timing
    • Solution: Apply DMSO treatment precisely on the third day of culture, after cells have attached but before differentiation induction [2].
  • Cause: hiPSC colony density too high or low
    • Solution: Optimize seeding density for your specific cell line (e.g., 1×10⁴ cells/cm² for LUMC line) [2].
Problem: High Percentage of Off-Target Cells

Potential Causes and Solutions:

  • Cause: Incomplete priming of hiPSCs
    • Solution: Verify pluripotency status of starting population and ensure DMSO treatment duration is exactly 24 hours [2].
  • Cause: Old or degraded DMSO
    • Solution: Use fresh DMSO aliquots and avoid repeated freeze-thaw cycles. Properly store DMSO under anhydrous conditions [78].
Problem: Poor Organoid Morphology

Potential Causes and Solutions:

  • Cause: DMSO toxicity
    • Solution: Ensure DMSO concentration does not exceed 2%. Test lower concentrations (0.5-1%) for sensitive cell lines [1] [2].
  • Cause: Inconsistent matrix coating
    • Solution: Standardize extracellular matrix preparation (e.g., Geltrex) to ensure uniform organoid development environment [2].

Table 1: Key Experimental Findings from DMSO Treatment Studies

Parameter Control (No DMSO) With DMSO Treatment Measurement Method Reference
SIX2+ Nephron Progenitors Baseline Significantly enhanced Immunofluorescence, Flow Cytometry [1] [2]
DE Differentiation Efficiency 29.6% CD117+CXCR4+ cells 81.3% CD117+CXCR4+ cells (with 0.8% DMSO) Flow Cytometry [76]
Activin A Requirement for DE 100 ng/ml 6.25 ng/ml (with 0.8% DMSO) SOX17+ cell quantification [76]
Optimal DMSO Concentration N/A 1-2% Multiple marker analysis [1] [2]
Treatment Duration N/A 24 hours prior to differentiation Protocol optimization [2]

Table 2: Research Reagent Solutions for DMSO-Enhanced Kidney Organoid Differentiation

Reagent Function Specifications & Notes
Medical Grade DMSO Priming agent for enhanced differentiation Use high-purity (≥99%), sterile-filtered. Store in aliquots at -20°C [77].
Geltrex/Matrigel Extracellular matrix for 3D culture Use 1% coating solution. Keep on ice during handling to prevent polymerization [2].
mTeSRPlus Medium hiPSC maintenance Includes necessary factors for pluripotency maintenance before differentiation [2].
Accutase Gentle cell dissociation Preferred over trypsin for hiPSC passaging to maintain viability [2].
Y-27632 (ROCK inhibitor) Enhances cell survival after passaging Use 10 µM during seeding to reduce anoikis [2].
Antibodies for Characterization Quality control assessment TRA-1-60, TRA-1-81, SSEA3/4 (pluripotency); SIX2, PODXL, LRP2 (kidney) [2].

Experimental Protocols

DMSO Pretreatment Protocol for Enhanced Kidney Organoid Differentiation

Based on: Kearney et al. Stem Cell Rev Rep 2025 [1] [2]

Day 1: Seeding hiPSCs

  • Dissociate hiPSC colonies using Accutase (1 mL/well of 6-well plate, 10 min at 37°C)
  • Prepare single cell suspension in mTeSRplus medium supplemented with 10 µM Y-27632
  • Seed onto cell culture plates pre-coated with 1% Geltrex at optimized densities:
    • LUMC line: 1×10⁴ cells/cm²
    • H101 line: 9×10³ cells/cm²
    • H107 line: 7×10³ cells/cm²
  • Incubate at 37°C, 5% CO₂

Day 2: Medium Refresh

  • Remove medium and replace with fresh mTeSRplus medium without Y-27632
  • Continue incubation at 37°C, 5% CO₂

Day 3: DMSO Treatment

  • Prepare mTeSRplus medium supplemented with 1-2% DMSO
  • Remove existing medium and add DMSO-containing medium
  • Incubate for 24 hours at 37°C, 5% CO₂

Day 4: Initiate Kidney Differentiation

  • Remove DMSO-containing medium
  • Proceed with standard kidney organoid differentiation protocol (e.g., Morizane et al. 2017)
  • Continue with specific differentiation timeline for nephron progenitor and kidney organoid formation
Quality Control Assessment

Pluripotency Marker Analysis (Post-DMSO Treatment)

  • Harvest cells using Accutase
  • For surface markers: Stain with TRA-1-81, TRA-1-60, SSEA3, SSEA4 antibodies
  • For intracellular markers: Fix, permeabilize, and stain with SOX2-PE and OCT3/4-AF647
  • Analyze by flow cytometry using BD Accuri C6 or similar
  • Expect moderate changes in pluripotency marker expression indicating primed state

Differentiation Efficiency Assessment (Day 9 of Differentiation)

  • Analyze SIX2 expression as key metanephric mesenchyme nephron progenitor marker
  • Use immunofluorescence or flow cytometry for quantification
  • Compare with non-DMSO treated controls for improvement assessment

Signaling Pathway and Workflow Diagrams

DMSO_Workflow cluster_Effects DMSO Molecular Effects Start hiPSC Culture (mTeSRPlus + Geltrex) Seed Day 1: Seed hiPSCs + Y-27632 Start->Seed Refresh Day 2: Refresh Medium (mTeSRPlus) Seed->Refresh DMSO_Treat Day 3: DMSO Treatment (1-2% for 24h) Refresh->DMSO_Treat Differentiate Day 4: Initiate Kidney Organoid Protocol DMSO_Treat->Differentiate G1_Arrest G1 Cell Cycle Arrest (via RB phosphorylation) Epigenetic_Change Epigenetic Landscape Modification PI3K_Pathway Altered PI3K Pathway Signaling Gene_Expression Altered Gene Expression (Cytoskeleton, Adhesion) Analyze Day 9+: Analyze Markers (SIX2, PODXL, LRP2) Differentiate->Analyze

DMSO Treatment Workflow and Molecular Effects

DMSO_Mechanism cluster_Cellular Cellular Level Effects cluster_Molecular Molecular Level Effects DMSO DMSO Treatment (1-2%) Cell_Cycle G1 Cell Cycle Arrest DMSO->Cell_Cycle Apoptosis Reduced Apoptosis DMSO->Apoptosis Morphology Colony Morphology Changes DMSO->Morphology Pluripotency Altered Pluripotency Transcription Factors Cell_Cycle->Pluripotency Leads to Signaling Enhanced Growth Factor Sensitivity (e.g., Activin) Apoptosis->Signaling Enables Epigenetic Modified Epigenetic Landscape Morphology->Epigenetic Associated with SMAD Increased SMAD2 Phosphorylation Pluripotency->SMAD Outcome Improved Nephron Progenitor Differentiation (Enhanced SIX2+ Cells) Pluripotency->Outcome Epigenetic->SMAD Epigenetic->Outcome Signaling->SMAD SMAD->Outcome

Proposed Mechanism of DMSO Action on Kidney Organoid Differentiation

The implementation of DMSO pretreatment represents a significant methodological advance in kidney organoid differentiation, directly addressing critical limitations in efficiency and reliability. By priming hiPSCs through cell cycle regulation and epigenetic modification, researchers can achieve more consistent differentiation into nephron progenitors with reduced off-target cells. While further research is needed to fully elucidate the mechanisms and optimize protocols across different hiPSC lines, the DMSO method offers a practical, cost-effective strategy to enhance kidney organoid quality for research and drug development applications.

Conclusion

The preconditioning of hiPSCs with low-dose DMSO represents a straightforward, reproducible, and powerful strategy to overcome a major bottleneck in kidney organoid research—differentiation efficiency. By priming the cells for a renal fate, this method consistently enhances the generation of critical SIX2+ nephron progenitors and promotes the development of more structurally defined kidney organoids. This advancement promises to yield more reliable and physiologically relevant human in vitro models, accelerating drug discovery and safety testing by providing a superior platform for modeling kidney development, disease, and injury. Future research should focus on elucidating the precise molecular mechanisms downstream of DMSO and exploring its synergistic potential with other emerging techniques, such as organ-on-a-chip systems, to further push the maturation and functional complexity of these tissues.

References